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ABSTRACT 
 
 
Protein phosphorylation is a post translational modification of 
proteins in which a serine, a threonine or a tyrosine residue is 
phosphorylated by an enzyme, kinase. Phosphorylation of proteins is a 
reversible and very important regulatory mechanism that occurs in 
both prokaryotes and eukaryotes. Phosphorylation turns many protein 
enzymes on and off, preventing or causing many diseases such as 
diabetes, cancer and rheumatoid arthritis. The phosphorylation on 
tyrosine residues of proteins is essential for transmission of signals for 
cell growth, proliferation and differentiation. Protein tyrosine 
phosphatases (PTPs) in concert with protein tyrosine kinases (PTKs) 
regulate many signal transduction pathways by controlling the degree 
of phosphorylation of tyrosine residues within the protein. While the 
roles and mechanisms of protein tyrosine kinases are well 
documented, our present understanding of protein tyrosine 
phosphatases is very limited. In this regard we still have much more to 
learn about PTPs. Here we propose the design and synthesis of novel 
protein tyrosine phosphatase mimetics and their activity against 
tyrosine phosphatases. Chapter two describes the synthesis of 2-
aminopyrimidine chlorides, sulfonamides and the sequence of 
reactions to make its amino acid analog. Chapter three describes the 
synthesis of α-aryl, α,β-epoxy carboxylates, phosphonates and their 
xiii 
 
xiv 
 
biological activity against tyrosine phosphatases. These compounds 
could be very helpful in significantly improving the current 
understandings about the roles and mechanisms of the PTPs. These 
proposed tyrosine phosphatase inhibitors are believed to work 
effectively in treating the diseases by modulating the phosphorylation 
in signal transductions pathways. Chapter four describes the design 
and the synthesis of Peptide Nucleic Acids (PNAs) both standard as 
well as hybrid PNAs with novel cysteine based monomers that are 
aimed to increase the cellular uptake by introducing positively charged 
or amphipathic species attached to cysteine thiol functional group. 
 CHAPTER ONE 
PROTEIN PHOSPHATASE INHIBITORS 
 
1.1 General introduction to phosphorylation 
 
Phosphorylation is the addition of an inorganic phosphate group 
to an organic molecule or a protein. It creates adenosine triphosphate 
(ATP), an energy storing molecule, from adenosine diphosphate (ADP) 
by the addition of an inorganic phosphate group in living cells (Figure 
1.1). ATP, also known as the energy currency of the cell, is the form of 
energy needed to sustain our cells and thereby sustain every living 
organism.1,2 Protein phosphorylation in particular is an important 
cellular process of living organisms both prokaryotes and eukaryotes. 
It has immense potential in understanding and curing some of 
challenging diseases and this is evident from the thousands of 
research articles being published on this topic every year in chemistry 
and biochemistry disciplines. Phosphate groups on a protein were first 
identified by Phoebus A. Levene in vitellin in 19063 and this 
observation was confirmed by Fritz Lipmann in 1933 in casein.4 
Enzymatic protein phosphorylation was then described for the first 
time by Eugene P. Kennedy in 1954.5 
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Figure 1.1. Oxidative phosphorylation in the biosynthesis of ATP 
 
Phosphorylation plays a crucial role in many cellular processes as 
in biological thermodynamics, enzyme activation, enzyme inhibition, 
protein-protein recognition, and protein degradation. Phosphorylation 
of ATPase during the transport of the metal ions Na+ and K+ across the 
cell membrane in osmoregulating to maintain homeostasis of the 
body’s water content,6 phosphorylation of the enzyme GSK-3 by 
protein kinase B (AKT) as part of the insulin signaling pathway,7 
phosphorylation of src tyrosine kinase by Csk,8 phosphorylation of 
NADPH oxidase9 are a few examples which indicate the significance of 
phosphorylation. It’s been recognized that phosphorylation of some 
proteins causes them to be degraded by the ATP-dependent 
ubiquitin/proteaosome pathway. These target proteins will become 
substrates for particular E3 ubiquitin ligases only when they are 
phosphorylated.10 
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1.2 Protein phosphorylation 
Enzymatic protein phosphorylation is a reversible process in 
most living organisms on the planet. Kinases catalyze the 
phosphorylation and phosphatases catalyze dephosphorylation. 
Reversible protein phosphorylation is the basis for the regulation of 
diverse cellular processes that include cellular metabolism, 
contractility, transport, cell division, differentiation and development, 
learning and memory.11-13  
 
Figure 1.2 Reversible phosphorylation on protein controlled by kinase 
and phosphatase enzymes 
 
The extent of phosphorylation and dephosphorylation turn many 
enzymes on and off by changing the conformation of the 
corresponding enzymes and the active sites of the receptors. The usual 
3 
 
sites of phosphorylation on the proteins are the amino acid moieties 
which have hydroxyl functional groups as in serine, threonine and 
tyrosine. In primitive organisms the sites of the phosphorylation also 
include histidine, arginine, cysteine and lysine (Figure 1.3).14 
Phosphorylation increases the hydrophilicity of the particular group 
and can sometimes occur on the side chains of the amino acids that 
are otherwise in hydrophobic protein patches such as occurs on the 
p53 tumor suppression protein.15 The sensitive cells on the retina get 
activated upon phosphorylation and then they process the incoming 
light in the signal transduction. The extraordinary diversity of both 
kinases (over 500) and phosphatases (over 100) that have been 
identified in the human genome itself speaks to the essential roles 
these proteins play in daily biological processes taking place in the 
body.16 
 
Figure 1.3 Typical amino acid residues for phosphorylation (second 
row amino acids are phosphorylation sites in primitive 
organisms)17 
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Phosphorylated proteins can be dephosphorylated by either 
specific phosphatases like serine/threonine specific or tyrosine specific 
phosphatases or non specific phosphatases like alkaline phosphatases. 
1.3. Occurrence of protein phosphorylation 
Protein phosphorylation can occur on multiple sites in the same 
protein at any given time and it is estimated that approximately 30% 
of the 10000 proteins in a typical mammalian cell are thought to be 
phosphorylated at any given time.18 This suggests that many cellular 
functions could be artificially altered if one could control the activity of 
kinases or phosphatases or both. This led to enormous interest in 
identifying and studying small molecules both peptidic and non-
peptidic, on specific kinases and phosphatases. Since the 
phosphorylation is crucial for stabilizing a particular conformation of a 
protein in order to act as an enzyme or as signal transduction element 
it is very important to know the state of phosphorylation of the protein 
to understand the structure and function of the same. 
As mentioned earlier the major sites of phosphorylation in 
advanced organisms, including human beings, are serine, threonine 
and tyrosine. Tyrosine sites are very rare sites for phosphorylation; 
however the corresponding proteins are easily purified by antibodies 
and hence well understood.19  
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1.4 Protein phosphatases and their importance 
Protein phosphatases (PPs) are an important sub family of 
enzymes that remove phosphate groups from proteins and work 
exactly opposite to the function of protein kinases which phosphorylate 
proteins and together these opposing enzymes maintain the 
equilibrium at right levels. Protein phosphatases were initially classified 
into families based on their dephosphorylation sites whether they 
dephosphorylate Threonine/Serine residues, Tyrosine residues (PTPs) 
or both of them (dual specific phosphatases-DSPs). But now it has 
been discovered that certain Ser/Thr specific enzymes can 
dephosphorylate Tyr, and many of the enzymes in the dual specific 
family based on the sequence can selectively function on Tyr, Ser, and 
Thr, RNA or phosphoinositides.  
Some important phosphatases include CD45, PTP1B, PTP1N, 
TCPTP, SHP-2, LAR, PP2C, Ppz1p, Ppz2p. CD45 is present in human 
hematopoietic cells and its mutation may lead to dysfunction of B 
lymphocytes and low T cell production which can lead to 
immunodeficiency. PTP1B is a negative regulator of insulin and is 
considered as a potential therapeutic target to treat type-II diabetes. 
TC-PTP is prominent in hematopoietic cell types and plays critical role 
in bone marrow maturation.20-22 
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1.5 Protein tyrosine phosphatases (PTPs) 
Protein tyrosine phosphatases (PTPs) are an important super 
family of enzymes which remove phosphate groups from 
phosphorylated tyrosine residues on proteins and regulate many signal 
transduction pathways, including growth initiation, propagation and 
termination, by regulating the extent of phosphorylation by working in 
association with the kinases in reciprocal directions. Defects in PTPase 
activity can lead to aberrations in the phosphorylation of tyrosine, 
eventually leading to protein malfunction, which contributes to the 
many human diseases like cancer, diabetes, obesity and rheumatoid 
arthritis. In recent days, PTPases have gained importance as the drug 
discovery target because of its critical role in bioprocesses. There are 
many classes of molecules being synthesized and studied for their 
activity on phosphatases some of which are shown in the Figure 1.6.23  
Obesity is the second largest cause of preventable deaths after 
smoking in the United States. Obese people are more prone to develop 
associated diseases than the people with normal weight like diabetes, 
heart diseases, strokes, high blood pressure, cancer and obstructive 
sleep apnea. 0.6 Million people are estimated to die because of cancer 
in the US alone which is alarming (Figure 1.4) 
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 Figure 1.4. Leading causes of death in US (2009) in adults over 25 
years24 
 
Type II diabetes alone afflicts over 200 million people worldwide 
and many more are unaware they are at high risk. The number of 
people diagnosed is expected to grow steadily over the next several 
years. Type II diabetes (non insulin-dependent diabetes mellitus 
(NIDDM) or T2DM), is characterized by a resistance to insulin which 
can be due to the ignorance of the body to the insulin which is 
necessary for the body to be able to process glucose for the required 
energy needs or because of inadequate beta cell activity and it 
accounts for 90% of all diabetic patients. Increased fatty acid oxidation 
contributes greatly to hyperglycemia by formation of high levels of 
acetyl-coenzyme A, ATP, and NADH, which increase gluconeogenesis 
and thus hepatic glucose production. Type I diabetes, insulin-
dependent diabetes mellitus (IDDM or T1DM), results from a lack of 
production or under production of insulin. When we eat food, the body 
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processes all of the sugars and starches into glucose, which is the 
energy currency of the cell. Insulin signals cells to take the sugar from 
blood. In diabetic conditions, glucose builds up in the blood instead of 
going into cells.25  
1.6 Phosphotyrosine mimetics 
The discovery of a PTP1B knockout as a non lethal mutation with 
increased insulin sensitivity by Elechbly et al has lead to the realization 
among the scientific community that the inhibition of protein tyrosine 
phosphatases might be a valuable research tool for insulin biology 
research.26 It could also be a possible source of drug development for 
treating major diseases like diabetes and obesity. The research in this 
field can lead to treatments of infectious agents, neurological 
disorders, autoimmune and certain cancers. To understand the 
function of phosphatases and in particular tyrosine phosphatases 
various molecules were developed and studied to find the exact 
mechanism of action of various phosphatases. Some of the well 
studied mimetics are shown in Figure 1.5.  
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 Figure 1.5 Phosphotyrosine and commonly used pTyr mimetics27 
 
1.7 Phosphatase inhibitors 
The initial findings of the PTP1B knock out experiments lead to 
the tremendous interests in both academia and industry to develop 
and study peptidic and non-peptidic molecules as the potential 
inhibitors of the protein phosphatases. The first crystal structure for 
PTP1B has been solved by Tonks et al in 1994.28 There are currently 
around 20 phosphatases with crystal structures that been solved. The 
crystal structure findings are valuable for the design of new inhibitors 
as they showed the secondary sites, some times called satellite sites, 
clearly in addition to the primary active sites. It’s been common to 
design molecules to interact with the secondary sites in addition to the 
active site increasing the specificity of the inhibitor to target desired 
10 
 
phosphatase enzymes. Some representative molecules are shown in 
the Figure 1.6.  
 
 
Figure 1.6 Some representative phosphatase inhibitors29-30 
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1.8 Challenges in designing a potent & specific phosphatase 
inhibitor 
The evolution of all of the phosphatases is believed to be from 
the same ancestor according to some of the biologists and it explains 
the very close similarities among phosphatases.31 All protein tyrosine 
phosphatases carry a highly conserved active site signature motif, [the 
(H/V)CX5R(S/T) amino acid sequence], which adopts a unique loop 
structure and employ a common catalytic mechanism. They have 
similar core structure made of a central parallel beta sheet with 
flanking alpha helices containing a β-loop and α-loop surrounding 
signature motif.32 The functions and specificity of these proteins are 
attributed to the regulatory domains and subunits. Because of the 
close similarities among the PTPs, it is known to be very difficult to 
selectively target specific PTPase and PTP1B in particular. For example 
PTP1B is closely related to TC-PTP and almost 80% of the sequence is 
similar in both of these phosphatases. This makes it very challenging 
to control selectivity. Some of the best known phosphatase inhibitors 
are shown and their biological activities and selectivities are compared 
in the Figure 1.7.33 
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 Figure 1.7 Activity and selectivity of some prominent inhibitors 
 
In addition to the similarities in structures specific PTPase may 
also regulate multiple signaling pathways and similarly one signaling 
pathway can be regulated by multiple PTPases.34  
In human beings proteins are predominantly phosphorylated on 
three residues Ser, Thr and Tyr residues, with each accounting for 
approximately 86%, 12% and 2% respectively. Human DNA encodes 
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~ 520 protein kinases, with nearly 428 known or predicted to 
phosphorylate Ser and Thr residues and 90 belonging to the tyrosine 
kinase family. In contrast there are only ~ 107 human phosphatases 
and only around 81 are predicted to be active protein phosphatases 
(based on human genome findings).35-38  
In addition, since the active site of PTP1B is highly hydrophilic, it 
remains a challenge to identify inhibitors with both excellent in vitro 
potency and drug-like physiochemical properties which would lead to 
good in vivo activities. Major breakthroughs in designing potent 
inhibitors have to address the following two important issues 1) Many 
PTPs have similar structures and sequences in their active site regions. 
This makes it more difficult to design inhibitors that are specific for the 
corresponding target. 2) Most of the small molecules that bind with 
high affinity in these active sites are hydrophilic leading to poor cell 
permeability.39-40 
1.9 PTP1B as an exciting target for therapeutic drug discovery 
Since the findings of PTP1B as a target for finding new drugs to 
the existing problems of obesity and diabetes in biology, many 
research groups have come up with different functional units based on 
theoretical and experimental results both peptidic and non peptidic 
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molecules. It is worth to mention some of the molecules reached to 
clinical trials II and failed to reach further due to efficacy issues.41-42  
1.10 PTP1B mechanism of action 
The protein tyrosine phosphatase PTP1B became an exciting 
target for the treatment of type II diabetes and obesity. The enzyme is 
a negative regulator of the insulin signaling pathway acting by 
dephosphorylating phosphotyrosine residues in the insulin receptors 
(IRs) and insulin receptor substrates (IRSs). To date more than 20 
PTPs have been solved for their crystal structures.43 The PTPs are 
composed of β-barrels flanked by α-helices. The catalytic site is 
located in a groove at the protein surface which is 9 Å deeper for 
classical PTPs compared to DSPs which are 6 Å deep. This difference is 
responsible for the higher substrate selectivity of the classical PTPs. 
Recognition of the substrate peptide sequence by PTP1B and binding of 
the phosphotyrosine deep in the catalytic site of the phosphate-binding 
loop (P-loop) are mediated by residues 214-221. The WPD loop 
consisting  of tryptophan, proline and aspartic acid closes down onto 
the substrate and thereby positions the thiolate of cysteine 215 for 
nucleophilic attack at the electrophilic phosphorous on the 
phosphotyrosine. Aspartic acid 181 acts as a general acid catalyst. This 
mechanism eventually hydrolyses to give inorganic phosphate group 
15 
 
which diffuses from the active site and gets replaced with water 
molecule. (Figure 1.7)44-45 
 
 
Figure 1.8 PTP1B mechanism of action 
 
After carefully looking at current molecules being used as 
inhibitors and understanding the PTP1B mechanism of action we herein 
propose design and synthesis of molecules which we believe could 
work as non covalent46 or covalent inhibitors47 for different 
phosphatases paying particular attention to inhibit PTP1B selectively 
(Figure 1.8 and Figure 1.9). Pyrimidine chloride 2.24 is particularly 
interesting as we will use this molecule to insert into small peptide and 
study its effect as it is our belief that this will increase the selectivity 
dramatically.48-50 
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 Figure 1.9. Proposed pyrimidine based phosphatase inhibitors  
 
 
Figure 1.10. Proposed epoxy and aziridine based phosphatase 
inhibitors 
 
1.11 Conclusion 
 
It’s been challenging to discover potent cell permeable and orally 
bioavailable PTP1B inhibitors. The highly cationic nature of the active 
site and the lack of adjacent hydrophobic binding sites have been 
obstacles in developing potent inhibitors. In this regard, we designed 
some of the molecules shown in Figures 1.8 and 1.9 as phosphatase 
17 
 
inhibitors and synthesized some of them and tested for their activity 
against protein tyrosine phosphatases (PTPs) and the activities are 
tabulated in the respective chapters. 
 
1.12 References 
1. Cohen, P. The origins of protein phosphorylation. Nat. Cell. Biol. 
2002, 4 (5), 127-130.  
2. Lipmann, F. A.; Levene, P. A. Serinephosphoricacid obtained on 
hydrolysis of vitellinic acid. J. Biol. Chem. 1932, 98 (1), 109-
114. 
3. Levene, P. A.; Alsberg, C. L. The Cleavage of Products of Vitellin. 
J. Biol. Chem. 1906, 2 (1), 127-133. b) Kenner, K. A.; 
Anyanwu, E.; Olefsky, J. M.; Kusari, J. Protein tyrosine 
phosphatase 1B is a negative regulator of insulin- and insulin-
like growth factor-I-simulated signaling. J. Biol. Chem. 1996, 
271, 19810-19816. 
4. Burnett, G.; Kennedy, E. P. The Enzymatic Phosphorylation of 
Proteins. J. Biol. Chem. 1954, 211 (2), 969-980. 
5. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, 
S.; Loy, A.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, 
C. Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, 
B. P. Increased insulin sensitivity and obesity resistance in mice 
18 
 
6. Combs, A. P. Recent advances in the discovery of competitive 
protein tyrosine phosphatase 1B inhibitors for the treatment of 
diabetes, obesity, and cancer. J. Med. Chem. 2010, 53, 2333-
2344. 
7. van Weeren, P. C.; de Bruyn et al. Essential role for protein 
kinase B (PKB) in insulin-induced glycogen synthase kinase 3 
inactivation. Characterization of dominant-negative mutant of 
PKB. J. Biol. Chem. 1998, 273 (21), 13150-13156. 
8. Cole PA, Shen K, Qiao Y, Wang, D. "Protein tyrosine kinases Src 
and Csk: a tail's tale". Curr Opin Chem Biol. 2003, 7 (5): 580–
585. 
9. Tonks, N. K.; Muthuswamy, S. K. A break becomes an 
accelerator: PTP1B - a new therapeutic target for breast cancer. 
Cancer Cell 2007, 11, 214-216. 
10. Easty, D.; Gallagher, W.; Bennett, D. C. Protein tyrosine 
phosphatases, new targets for cancer therapy. Curr. Cancer 
Drug Targets. 2006, 6, 519-532. 
11. Hunter, T. Signaling—2000 and beyond. Cell 2000, 100, 113-
127. 
19 
 
12. Pawson, T. Dynamic control of signaling by modular adapter 
proteins. Curr. Opin. Cell. Biol. 2007, 19, 112-119. 
13. Burke, T. R.; Kole, H. K.; Roller, P. P. Potent inhibition of insulin 
receptor dephosphorylation by a hexamer peptide containing the 
phosphotyrosine mimetic F2Pmp. Biochem. Biophys. Res. 
Commun. 1994, 204, 129-134. 
14. Cozzone, A. J. Protein phosphorylation in prokaryotes. Annu. 
Rev. Microbiol. 1988, 42, 97-125. b). Stock, J. B.; Ninfa, A. J.; 
Stock, A. M. Protein phosphorylation and regulation of adaptive 
responses in bacteria. Microbiol. Rev. 1989, 53 (4), 450-490. 
15. Bates, S.; Vousden, K. H. p53 is signaling checkpoint arrest or 
apoptosis. Curr. Opin. Genet. Dev. 1996, 6 (1), 12-18. 
16. Cho, U.S.; Xu, W. Crystal structure of the protein phosphatase 
2A heterotrimeric holoenzyme. Nature, 2006, 445, 53-57. 
17. Quezada, C. M.; Hamel, D. J.; Gradinaru, C.; Bilwes, A. M.; 
Dahlquist, F. W.; Crane, B. R.; Simon, M. I. Structural and 
Chemical Requirements for Histidine Phosphorylation by the 
Chemotaxis Kinase CheA. J. Biol. Chem. 2005, 280 (34) 30581-
30585. 
18. Piggee, C. Phospoproteomics: Miles To Go Before It’s Routine. 
Anal. Chem. 2009, 81, 2418-2420 
20 
 
19. Zhao, Z.; Bouchard, P.; Diltz, C. D.; Shen, S. H.; Fisher, E. H. 
Purification and characterization of a Protein Tyrosine 
Phosphatase containing SH-2 domains. J. Biol. Chem. 1993, 
268, 2816-2820. 
20. Ostergaard, H. L.; et al. Expression of CD45 alters 
phosphorylation of the lck-encoded tyrosine protein kinase in 
murine lymphoma T-cell lines. Proc. Natl. Acad. Sci. USA, 1989, 
86, 8959-8963. 
21. Neel BG, Gu H, and Pao L (2003) The ‘Shp’ing news: SH2 
domain-containing tyrosine phosphatases in cell signaling. 
Trends Biochem Sci 2003, 28, 284–293. 
22. a). Johnson, K. G.; Van, V. D Receptor protein tyrosine 
phosphatases in nervous system development. Physiol Rev 
2003, 83, 1–24. b). Krueger, N. X.; et al. The transmembrane 
tyrosine phosphatase DLAR controls motor axon guidance in 
Drosophila. Cell, 1996, 84, 611-622. 
23. a). Combs, A. P. Recent advances in the discovery of competitive 
protein phosphatase 1B inhibitors for the treatment of diabetes, 
obesity and cancer. J. Med. Chem. 2010, 53, 2333-2344 b). 
Ahn, J. H.; Cho, S. Y. et al Protein Tyrosine Phosphatase 1B 
Inhibitors: Catechols. Bull. Korean. Chem. Soc. 2003, 24 (10), 
1505-1508. c). Heneberg, P. Use of protein tyrosine phosphatase 
21 
 
24. Centers for Disease Control / National Center for Health 
Statistics 2009 review. 
25. Lin, Y.; Sun, A. Current views on type 2 diabetes. Journal of 
Endocrinology, 2010, 204, 1-11. 
26. Eichebly, M.; Payette, P.; Mihaliszyn, E.; Cromlish, W.; Collins, 
S.; Loy, A. L.; Normandin, D.; Cheng, A.; Hagen, H. J.; Chan, C. 
C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; 
Kennedy, B. P. Increased Insulin Sensitivity and Obesity 
Resistance in Mice Lacking the Protein Phosphatase- 1B Gene. 
Science, 1999, 283, 1544-1548. 
27. Imhof, D.; Wieligmann, K.; Hampel, K.; Nothmann, D.; Zoda, M. 
S.; Arra, S. D.; Zacharias, M.; Bohmer, F. D.; Reissmann, S. 
Synthesis and Biological Evaluation of Linear and Cyclic 
Phosphopeptide Ligands of the N-Terminal SH2 Domain of 
Protein Tyrosine Phosphatase SHP-1. J. Med. Chem., 2005, 48, 
1528-1539. 
22 
 
28. a). Barford, D.; Flint, A. J.; Tonks, N. K. Crystal structure of 
Human Protein Tyrosine Phosphatase 1B. Science 1994, 263, 
1397-1404. b). Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. 
et al. Large-Scale Structural Analysis of Classical Human Protein 
Tyrosine Phosphatome. Cell 2009, 136, 352-363. 
29. Johnson, T. O.; Ermolieff, J.; Jirousek, M. R. Protein Tyrosine 
Phosphatase 1B Inhibitors for Diabetes. Nature 2002, 1, 697-
709. B). Bialy L.; Waldmann, H. Inhibitors of Protein Tyrosine 
Phosphatases: Next-Generation Drugs? Angew. Chem. Int. Ed, 
2005, 44, 3814-3839. 
30. Ghosh, M.; Sanders, T. C.; Zhang, R.; Seto, C. T. Inhibition of 
Phosphatase Activity by Positively-Charged Cyclodextrins. Org. 
Lett., 1999, 1 (12), 1945-1948. 
31. Kennelly, P. J. Protein Phosphatases – A Phylogenetic 
Perspective. Chem. Rev. 2001, 101 (8), 2291-2312. 
32. Wishart, M. J.; Denu, J. M.; Williams, J. A.; Dixon, J. E. A Single 
Mutation Converts a Novel Phosphotyrosine Binding Domain into 
a Duel-specificity Phosphatase. J. Biol. Chem. 1995, 270, 
26782-26785. 
33. Combs, A. P.; et al. Structure-based design and discovery of 
protein tyrosine phosphatase inhibitors incorporating novel 
isothiazolidinone heterocyclic phosphotyrosine mimetics. J. Med. 
23 
 
Chem. 2005, 48, 6544-6548. B). Barnes, D.; Coppoa, G. M.; 
Stams, T.; Topiol, S. W.; Waring, J. R. Preparation of Thiadiazole 
Derivatives as Antidiabetic Agents. PCT Int. Appl, 2008, WO 
2008148744, 36 pp (Novartis A.-G., Switzerland; Novartis 
Pharma G. m. b. H.) 
34. Camps M.; Nichols A.; Arkinstall S. Dual specificity 
phosphatases: a gene family for control of MAP kinase functions. 
FASEB J. 2000, 14 (1): 6–16. 
35. Dunham, I. et al. The DNA sequence of human chromosome 22. 
Nature. 1999, 401, 489−495  
36. Zhan, X. L.; Wishart, M. J.; Guan, K. L. Nonreceptor Tyrosine 
Phosphatases in Cellular Signaling: Regulation of Mitogen-
Activated Protein Kinases. Chem. Rev. 2001, 101, 2477-2496.M 
37. International Human Genome Sequencing Consortium (2004). 
Finishing the euchromatic sequence of the human genome. 
Nature 2004, 431, 931–945. 
38. International Human Genome Sequencing Consortium. Initial 
sequencing and analysis of human genome. Nature, 2001, 409, 
860-921. 
39. Yamaguchi, H. et al. Substrate specificity of the human protein 
phosphatase 2Cδ, Wip1. Biochemistry 2005, 44, 5285–5294  
24 
 
40. Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine 
phosphatases: next-generation drugs? Angew. Chem. Int. Ed. 
2005, 44, 3814-3839. 
41. Shrestha, S.; Battarai, B. R.; Cho, H.; Choi, J. K. PTP1B Inhibitor 
Ertiprotafib is also a potent IkB kinase β (IKK β) Bio. Med. Chem. 
Lett 2007, 17 (10), 2728-2730. 
42.  Cohen, P. The twentieth century struggle to decipher insulin 
signalling. Nature Rev. Mol. Cell Biol. 2006, 7, 867–873. 
43. Sivaramakrishnan, S.; Keerthi, K.; Gates, K. S. A Chemical 
Model for Redox Regulation of Protein Tyrosine Phosphatase 1B 
(PTP1B) Activity. J. Am. Chem. Soc. 2005, 127 (31), 10830-
10831. b) Xing, Y. et al. Structure of protein phosphatase 2A 
core enzyme bound to tumor-inducing toxins. Cell, 2006, 127, 
341-353. 
44. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. et al. Large-
Scale Structural Analysis of Classical Human Protein Tyrosine 
Phosphatome. Cell 2009, 136, 352-363. b) Alonso, A.; Sasin, J.; 
Bottini, N.; Friedberg, I.; Friedberg, A.; Osterman, A.; Godzik, 
A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein Tyrosine 
Phosphatases in the Human Genome. Cell, 2004, 117, 699-711. 
25 
 
45. Zhang, Z. Y. Chemical and Mechanistic Approaches to the Study 
of Protein Tyrosine Phosphatases. Acc. Chem. Res. 2003, 36, 
385-392. 
46. Lundblad, R. L. Chemical reagents for Protein Modification. CRC 
Press Inc. 2004. ISBN 0-8493-1983-8. 
47. a). Park, J.; Fu, H.; Pei, D. Peptidyl Aldehydes as Reversible 
Covalent Inhibitors of Src Homology 2 Domains. Biochemistry. 
2003, 42 (17), 5159-5167. b). Park, J.; Pei, D. trans-β-
Nitrostyrene Derivatives as Slow-Binding Inhibitors of Protein 
Tyrosine Phosphatases. Biochemistry. 2004, 43 (47), 15014-
15021. c). Park, J.; Fu, H.; Pei, D. Peptidyl Aldehydes as 
Reversible Covalent Inhibitors of Protein Tyrosine Phosphatases. 
Biochemistry, 2002, 41 (34), 10700-10709. 
48. Hooft van Huijsduijnen, R.; Sauer, W. H. B.; Bombrum, A.; 
Swinnen, D. Prospects for inhibitors of protein tyrosine 
phosphatase 1B as antidiabetic drugs. J. Med. Chem. 2004, 47, 
4142-4146. 
49. Bence, K. K.; et al. Neuronal PTP1B regulates body weight, 
adiposity and leptin action. Nature Medicine, 2006, 12, 917-924. 
50. a). Cohen. P. The Past and future of Protein Phosphatase 
Research. Bioessays. 1994, 16, 583-588. b). Moorhead, B. G.; 
26 
 
27 
 
et al. Emerging roles of nuclear protein phosphatases. Nature. 
2007, 8, 234 244. 
 
 CHAPTER TWO 
SYNTHESIS OF NOVEL 2-AMINOPYRIMIDINE CHLORIDES, 
SULFONAMIDES AND ITS AMINO ACID ANALOG 
2.1 General introduction 
 
Ever since the introduction of synthetic sulfonamide drugs 
(popularly known as sulfa drugs) as antibiotics in the early 1930s, 
there has been significant attention being paid to the discovery of new 
and effective drugs with the sulfonamide functional group. There are 
currently over 15,000 sulfonamide derivatives, analogs and related 
compounds, which have been synthesized and tested for different 
diseases. This studies lead to the discovery of so many useful 
sulfonamide medicines for treating urinary, thyroid, heart diseases, 
malarial infection and leprosy along with many other diseases.1  
 
Sulfonamide drugs were the first antimicrobial agents 
administered in combination with antibiotics for the treatment of 
infection. When penicillin and streptomycin first became available they 
were often given in combination with sulfonamides in which cases they 
became less effective by themselves.2 In some instances they were 
used as additives and in some they acted synergistically. In 1932, 
German chemist Gerhard Domagk discovered that a dye called 
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Prontosil controlled streptococcal infections in mice for which he later 
received the Nobel Prize in 1939 in the field of Physiology and 
Medicine.3 Prontosil was also found to control staphylococcal infections 
in rabbits without harming animals. Since then, sulfonamides have 
been clinically used for decades and have been found to have wide 
ranging biological activities including antiviral, antidiabetic 
(hypoglycemic), diuretic, and antithyroid activities and also antitumor 
agents.4-6 The sulfonamide functional group is present in well 
established thiazide diuretics, loop diuretics, sulfonyl ureas, COX-2 
inhibitors,7 anti-inflammatory agents, anti-rheumatics, anti-
ulceratives, acetazolamide and many more (Figure 2.1). Folate 
synthesis is the important step in the synthesis of bacterial cell wall. 
Antibacterial sulfonamides act as competitive inhibitors of the enzyme 
dihydropteroate synthetase; an enzyme involved in folate synthesis, 
and prevents the formation of cell wall which ultimately prevents the 
growth of bacteria. They have been also been used in retroviral 
therapy as HIV protease inhibitors recently.8 
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 Figure 2.1. Some important drugs with sulfonamide functional groups 
 
The compounds with sulfonamide functional group have became 
increasingly popular recently among medicinal chemists in part 
because of the ease of deprotonation at physiological pH in the body 
which makes them more water soluble, more drug-like properties, 
which is a fundamental requirement for any chemical entity to be used 
as an effective drug in treating any kind of diseases.9-12 
 
We, keeping in mind the fundamental principles of drug 
discovery low toxicity and cellular solubility, based our target 
molecules on commercially readily available 2-aminopyrimidine in part 
due to its low toxicity towards the living cells and the pKb of the NH 
proton in the product sulfonamide.13-14  
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 Figure 2.2 Proposed 2-aminopyrimidine derivatives as novel PTP1B 
inhibitors 
 
We focused our efforts to synthesize potent, yet highly selective 
inhibitors for individual members of the large PTPase family of 
enzymes paying particular attention to PTP1B. 15-17 In this regard, we 
came up with the 2-aminopyrimidine derived molecules shown in the 
Figure 2.2. The compound 2.8 is expected to work as a non covalent 
inhibitor. The other three compounds expected to work as either 
covalent or non covalent inhibitors due to the electrophilic character.18 
To increase the specificity of the inhibition for PTP1B we were 
interested in making a small peptide library, to obtain structure 
activity relationship (SAR) data, containing the amino acid derived 
chloride 2.24 shown in Figure 2.2. For this, we will employ solid phase 
peptide synthesis methods.19  
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Biological activity is explained briefly at the end of this chapter. 
Some of the key synthetic reactions in this chapter are the 
Sonogashira cross coupling, introduction of acetylene moiety and the 
deprotection of tert-butoxycarbonyl groups from the 1o amine group 
employing an environmentally friendly catalyst, Montmorillonite K-10 
clay. 
 
2.2 Results and discussion 
Professor Jerry Wu at the Moffitt Cancer Center collaborated with 
us by studying the biological activity of the compounds synthesized in 
this chapter.20 Dr. Wayne Guida’s group supported us with the design 
and modeling data for the same. Fenger Zhou’s contribution in scaling 
up intermediate 2.5 is also appreciated. 
 
Syntheses of all of the 2-aminopyrimidine derivatives discussed 
in this chapter were started from the commercially available 2-
aminopyrimidine. 2-Aminopyrimidine was reacted with 
methanesulfonyl chloride in pyridine as solvent to afford 2-
aminopyrimidine sulfonamide 2.1 in good yields.21 Reaction of the 
above sulfonamide with molecular iodine in the presence of mercuric 
acetate in hot 1,4-dioxane solvent afforded 5-iodo-2-N-
(methanesulfonyl)aminopyrimidine 2.2 in excellent yields.22 
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 Sulfonamide 2.2 was protected as the para-methoxybenzyl 
sulfonamide 2.3 employing very well established reaction conditions 
using para-methoxybenzyl chloride, KI and K2CO3 in DMF at ambient 
temperatures in very good yields.23 Pd (0) catalyzed Sonogashira 
coupling conditions24 were employed to introduce the desired alkyne 
functionality in the molecule using commercially available 2-methyl-3-
butyn-2-ol which gave alkyne-ol 2.4 in excellent yields. The same was 
deprotected using NaOH in toluene as solvent at reflux temperatures 
to afford intermediate alkyne 2.5 in moderate yields.25 (Scheme 2.1) 
 
 
 
Scheme 2.1 Synthesis of 5-ethynyl-2-N-[(4-methoxybenzyl) 
(methanesulfonyl)]-2-aminopyrimidine 2.5 
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Alkyne 2.5 and iodide 2.3 were subjected to the Sonogashira 
coupling conditions mentioned earlier to get the coupled product, the 
symmetrical alkyne 2.6, in very good yields which was subsequently 
hydrogenated over hydrogen gas using 10% (w/w) Pd over carbon26 
as catalyst in EtOH: EtOAc: DCM (12:12:1) solvent system to afford 
the symmetrical bipyrimidine 2.7 in quantitative yields. The para-
methoxy benzylamine 2.7 was deprotected to give the bipyrimidine 2.8 
in good yields.27 (Scheme 2.2) 
 
 
 
Scheme 2.2 Synthesis of symmetrical bipyrimidine sulfonamide 2.8 
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Next we needed 5-iodo-2-N-(di tert-butoxycarbonyl)pyrimidine 
as an intermediate to synthesize the chloro analogue 2.15. 
Commercially available 2-aminopyrimidine was subjected to aromatic 
electrophilic substitution reaction with molecular iodine and mercuric 
acetate in hot 1, 4-dioxane and water (3:1) at 70 oC to afford 5-iodo-
2-aminopyrimidine 2.9 in very good yields. The obtained amine was 
protected as a di tert-butyl dicarbamate 2.10 using di tert-butyl 
dicarbonate and DMAP in DMF at ambient temperatures.28 (Scheme 
2.3) 
 
 
 
Scheme 2.3 Synthesis of 5-iodo-2-N,N-di tert butoxycarbonyl 
bipyrimidine 2.10 
 
Alkyne 2.5 and iodide 2.10 were coupled under Sonogashira 
coupling conditions as previously mentioned to give alkyne 2.11 in 
good yields, which on hydrogenation gave bipyrimidine 2.12 in 
excellent yields. The product was heated to reflux in acetonitrile with 
montmorillonite K-10 clay to deprotect tert-butoxycarbonyl groups and 
obtain quantitative yields of 2.13 without needing further purification. 
Sulfonation with chloromethanesulfonyl chloride followed by the 
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deprotection of PMB group gave the desired chloride 2.15 in 34% 
yields for two steps29 (Scheme 2.4). 
 
 
 
Scheme 2.4 Synthesis of bipyrimidine sulfonyl chloride 2.15 
 
Suitably protected 5-iodo-pyrimidine chloride 2.18 was 
synthesized from 2-amino pyrimidine using the reaction conditions 
mentioned earlier. The PMB group was replaced by benzyl so as to 
make it compatible for the selective deprotection of the methyl ester30 
of amino acid derivative to get amine protected amino acid 2.24 ready 
to use in solid phase synthesis to make small peptides and convenient 
deprotection of benzyl group applying Pd catalyzed hydrogenation 
conditions. (Scheme 2.5) 
36 
 
  
 
Scheme 2.5 Synthesis of N-Benzyl-N-(5-iodo-pyrimidin-2-yl)-
chloromethanesulfonamide 2.18 
 
Readily available L-Serine was esterified using thionyl chloride to 
methyl ester 2.19 and the resulting HCl salt was reacted with di-tert 
butyl dicarbonate in the presence of potassium carbonate in THF:H2O 
(3:1) solvent to yield N-(tert-butoxycarbonyl)-L-serine methyl ester 
2.20 in quantitative yields.31 Tosylation with p-toluenesulfonyl chloride 
and subsequent iodination with NaI in acetone afforded the N-(tert-
butoxycarbonyl)-β-iodoalanine methyl ester 2.22 in excellent yields32 
which can be further coupled to iodide 2.18 using Pd2dba3 as the 
catalyst to get chloro sulfonamide 2.23.33 Selective hydrolysis of the 
methyl ester using sodium hydroxide in tetrahydrofuran can result in 
the orthogonally protected amino acid 2.24 which can be readily put 
into small peptides to increase the selectivity of the inhibition of 
selective phosphatase over closely related phosphatases. We will 
employ solid phase peptide synthesis to prepare a library of small 
peptides incorporating (Scheme 2.6) amino acid 2.24.  
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Scheme 2.6 Synthesis of 3-[2-(Benzyl-chloromethanesulfonyl-
amino)-pyrimidin-5-yl]-2-tert-butoxycarbonylamino-
propionic acid 2.24 
 
2.3 Biological activity studies 
The compounds synthesized in this chapter 2.8, 2.15 and 2.16 
were tested for their activity against SHP-2 and PTP1B but showed no 
significant activity. 
2.4 Conclusion 
Novel 2-aminopyrimidine chlorides and sulfonamides were 
synthesized and their application to synthesize amino acid analog 2.24 
with tert-butoxycarbonyl as protecting group for solid phase synthesis 
of small peptides were proposed and the synthesis was partially 
applied to achieve novel peptides as potential noncovalent inhibitors 
for tyrosine phosphatases. The final two steps shown in the scheme 
2.6 can be easily performed by utilizing the palladium catalyzed 
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coupling conditions and the subsequent hydrolysis of methyl ester to 
get 2.24.  
 
2.5 Experimental procedures 
 
2.5.1 General 
1H-NMR and 13C-NMR spectra were recorder on a Brucker 250 
MHz and the Varian 400 MHz spectrometer in CDCl3, Methanol-d4 and 
DMSO-d6 with TMS as the standard. Chemical shifts are reported in 
ppm, spin multiplicities are indicated by s (singlet), d (doublet), t 
(triplet), q (quartet), p (pentet), m (multiplet), dd (doublet of doublet) 
and bs (broad singlet). Thin-Layer chromatography (TLC) was 
performed on glass plates coated with 0.25 mm thickness of silica-gel. 
All solvents were dried and distilled prior to use and organic solvent 
extracts were dried over Na2SO4. Mass measurements were carried out 
on ESI LC MS system (Agilient Technologies) and High Resolution Mass 
measurements were done on LC MSD TOF system (Agilient 
Technologies). MALDI-TOF measurements were recorded on Autoflex 
(BRUKER) Melting points were recorded using Melt-Temp 
(Electrothermal) instrument and were uncorrected. 
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2-N(methanesulfonyl)-aminopyrimidine (2.1):- To a 250 mL two 
necked round bottomed flask equipped with nitrogen inlet was charged 
2-aminopyrimidine (32 g, 0.34 mol) followed by the addition of 
pyridine (128 mL) under positive pressure of nitrogen. The mixture 
was brought to 0 oC using an ice bath. A solution of methanesulfonyl 
chloride (72.1 g, 0.63 mol) in pyridine (96 mL) was added over a 
period of 10 minutes after which the reaction was brought to ambient 
temperatures in one hour. The reaction was stirred for another 10 
hours before concentrating under reduced pressure. Residual pyridine 
was removed azeotropically by evaporating with methanol (3×40 mL) 
before purifying the crude by recrystallization in methanol to get pure 
product 2-N-(methanesulfonyl)-aminopyrimidine 2.1 as an off-white 
solid. (38.3 g, 65.8%). 1H NMR (DPX 250 MHz, CDCl3) δ 11.32 (bs, 
1H, NH), 8.64 (d, J=5.0, 2H), 7.15 (t, J=5.0), 3.38 (s, 3H, CH3);  13C 
NMR (DPX 250 MHz, CDCl3) δ 158.54, 157.54, 115.72, 41.25; LCMS 
(ESI) m/z calcd for C5H7N3O2S 173.029 found 174.0 [M+H]+, mp 
256.3 oC. 
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5-iodo-2-N (methanesulfonyl) amino pyrimidine (2.2):- To a 1L 
three necked flask 2-N-(methanesulfonyl)-aminopyrimidine 2.1 (13.0 
g, 75.0 mmol) and glacial acetic acid (400 mL) were charged. The 
heterogeneous mixture was heated to 120 oC to dissolve all the solids 
which resulted in the light brown solution. Iodine (20.0 g, 78.8 mmol) 
was charged to the flask in one portion before cooling to room 
temperature at which Hg(OAc)2 was charged in one portion. After 5 
minutes of stirring at room temperature, the reaction was heated to 
120 oC for an hour. Reaction was monitored by thin layer 
chromatography. (The disappearance of iodine color indicates the 
completion of the reaction). The reaction mixture was carefully poured 
into 15% KI solution (975 mL) and stirred for another 30 minutes. 
Crude product was collected by filtration and the same was 
recrystallized from MeOH to get pure compound, 5-iodo-2-N-
(methanesulfonyl) aminopyrimidine 2.2, as an off-white solid. (19.28 
g, 85.8%) 1H NMR (DPX 250 MHz, CDCl3) δ 8.77 (s, 2H), 7.26 (s, 1H), 
3.44 (s, 3H); 13C NMR (DPX 250 MHz, DMSO-d6) δ 163.43, 156.19, 
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84.78, 41.12; LCMS (ESI) m/z calcd for C5H6IN3O2S 299.0895 found 
299.9 [M+H]+, mp 263.3 oC. 
 
 
 
5-iodo-2-N [(methanesulfonyl), (4-methoxybenzyl)] amino 
pyrimidine (2.3):  To a stirred solution of the  iodide 2.2 (2.0 g, 6.69 
mmol), KI (0.11 g, 0.67 mmol) and potassium carbonate (1.85 g, 
13.38 mmol) in 50 mL of dry DMF under nitrogen atmosphere was 
added p-methoxybenzyl chloride at room temperature. Upon 
completion of the reaction solvent was evaporated under vacuo and 
the residue was dissolved in ethyl acetate (80 mL) and the same was 
washed with water (2х15 mL) and brine (3х15 mL), successively. 
Organic layer was dried over anhydrous sodium sulfate and the solvent 
was evaporated under vacuo. The crude was subjected to the flash 
chromatography on silica gel using EtOAc/Hexane (2:8) as eluent to 
give pure compound 2.3 as a colorless liquid (2.16 g, 77.14%). 1H 
NMR (DPX 250 MHz, CDCl3) δ  8.64 (s, 1H), 7.25 (d, 2H, J=7.50), 6.74 
(d, 2H, J=7.50), 5.22 (s, 2H), 3.70(s, 3H), 3.26 (s, 3H); 13C NMR 
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(DPX 250 MHz, CDCl3) δ 162.95, 159.12, 157.54, 129.61, 129.07, 
113.89, 84.03, 55.25, 48.83, 42.91; HRMS (ESI) m/z calcd for 
C13H14IN3O3S 418.980 found 419.9 [M+H]+, mp 107.5 oC. 
 
 
 
5-[(2-hydroxy), (2-methyl)] butynyl-2-N [(methanesulfonyl), 
(4-methoxynenzyl)] amino pyrimidine (2.4): To a three necked 
round bottomed flask were added the iodide 2.3 (1.0 g, 2.38 mmol), 
alkyne (0.4 g, 4.77 mmol), CuI (22.7 mg, 0.12 mmol), PPh3 (62.5 mg, 
0.24 mmol), Pd (PPh3)4 (27.5 mg, 0.024 mmol), TEA (2.0 mL) followed 
by charging with 25 mL of dry acetonitrile.  The solution was brought 
to 60 oC. Upon completion of the reaction, in 10 hours, solvent was 
evaporated under vacuo. The crude was subjected to flash 
chromatography on silica gel using EtOAc/Hexane (2:8) as eluent to 
give pure compound 2.4 as a yellow fluffy solid (0.82 g, 92%). 1H NMR 
(DPX 250 MHz, CDCl3)  δ 8.58 (s, 2H), 7.33 (d, 2H, J=7.50 Hz), 6.81 
(d, 2H, J=7.50 Hz), 5.34 (s, 2H), 3.37 (s, 3H), 3.34 (s, 3H), 1.65 (bs, 
1H), 1.62 (s, 6H);   13C NMR (DPX 250 MHz, CDCl3) δ 159.78, 159.09, 
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157.07, 129.62, 129.18, 113.86, 112.91, 99.48, 75.40, 65.66, 55.24, 
48.71, 42.97, 31.32; LCMS (ESI) m/z calcd for C18H21N3O4S 375.1252, 
found, 376.1 [M+H]+. 
 
 
 
N-(5-Ethynyl-pyrimidin-2-yl)-N-(4-methoxy-benzyl)-
methanesulfonamide (2.5):- The alkyne-ol 2.4 (0.80 g, 2.13 mmol) 
and sodium hydroxide (0.22 g, 5.50 mmol) were taken in toluene (50 
mL) and the solution was heated to reflux for 10 hours. Upon 
completion of the reaction by TLC the solvent was evaporated under 
reduced pressure and the residue was extracted into EtOAc. The 
organic layer was further washed with brine solution and dried over 
anhydrous sodium sulfate. The solvent was removed under reduced 
pressure and the crude obtained was purified by flash chromatography 
to get pure acetylene 2.5 as a colorless solid (0.33 g, 49 %). 1H NMR 
(DPX 250 MHz, CDCl3)  δ 8.57 (s, 2H), 7.26 (d, 2H, J=10.0), 6.74 (d, 
2H, J=10.0), 5.26 (s, 2H), 3.69 (s, 3H), 3.28 (s, 3H); 13C NMR (DPX 
250 MHz, CDCl3)  δ 160.37, 159.13, 157.37, 129.61, 129.13, 113.89, 
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112.29, 83.08, 66.17, 55.24, 48.72, 43.00;   HRMS (ESI) m/z calcd for 
C15H15N3O3S 317.08, found 318.0 [M+H]+, mp 113.1 oC. 
 
 
 
N-(5-{2-[Methanesulfonyl-(4-methoxy-benzyl)-amino]-
pyrimidin-5-ylethynyl}-pyrimidin-2-yl)-N-(4-methoxy-benzyl)-
methanesulfonamide (2.6):- To a three necked round bottomed 
flask were added aryl iodide 2.3 (0.26 g, 0.63 mmol), alkyne 2.5 (0.20 
g, 0.63 mmol), CuI (5.9 mg, 0.031 mmol), PPh3 (16.5 mg, 0.063 
mmol), Pd(PPh3)4 (7.2 mg, 0.006 mmol) and TEA (2 mL) followed by 
25 mL of dry acetonitrile.  The solution was brought to 60 oC. Upon 
completion of the reaction, in 10 hours, the solvent was evaporated 
under vacuo. The crude was subjected to flash chromatography on 
silica gel using EtOAc/Hexane (2:8) as eluent to give pure symmetrical 
alkyne 2.6 as a yellow fluffy solid (0.28 g, 74 %). 1H NMR (DPX 250 
MHz, CDCl3)  δ 8.63 (s, 4H), 7.29 (d, 4H, J=10.0), 6.76 (d, 4H, 
J=10.0), 5.30 (s, 4H), 3.71 (s, 6H), 3.37 (s, 6H); 13C NMR (DPX 250 
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MHz, CDCl3)  δ 159.75, 159.15, 157.38, 129.67, 129.05, 113.89, 
112.38, 87.99, 55.26, 48.76, 43.03;  HRMS (ESI) m/z calcd for 
C28H28N6O6S2 608.1512, found 609.1592 [M+H]+, mp 212.4 oC. 
 
 
 
 
N-[5-(2-{2-[Methanesulfonyl-(4-methoxy-benzyl)-amino]-
pyrimidin-5-yl}-ethyl)-pyrimidin-2-yl]-N-(4-methoxy-benzyl)-
methanesulfonamide (2.7):- To a solution of alkyne 2.6 (0.27 g, 
0.44 mmol) in ethanol/EtOAc/DCM (12:12:1) (25 mL), 10% (w/w) 
palladium on carbon (0.1 g) was added carefully. The reaction was 
hydrogenated over H2 gas (45 psi) for 12 hrs. The resulting solution 
was filtered carefully over Celite and the Celite cake was washed with 
ethyl acetate (25 mL) to get most of the compound off of it. The 
organic filtrate was subjected to rotary evaporation to yield pure 
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product 2.7 needing no further purification (~ quant %). HRMS (ESI) 
m/z calcd for C28H32N6O6S2 612.1824 found 613.1929 [M+H]+. 
 
 
 
N-{5-[2-(2-Methanesulfonylamino-pyrimidin-5-yl)-ethyl]-
pyrimidin-2-yl}-methanesulfonamide (2.8):- Compound 2.7 was 
taken in round bottomed flask and cooled to 0 oC in an ice bath 
followed by the addition of neat TFA (5 mL). The resulting solution was 
stirred at room temperature for 2 hours. Upon completion of the 
reaction, the solvent was removed under reduced pressure and the 
residue obtained was dissolved in DCM and subjected to rotary 
evaporation to azeotropically remove the residual trifluoroacetic acid 
(3×15 mL). The crude product obtained was precipitated using diethyl 
ether to get pure sulfonamide 2.8 as an off-white solid in moderate 
yields (0.57 g, 35 %). 1H NMR (DPX 250 MHz, CDCl3) δ 11.44 (bs, 2H), 
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8.5 (s, 4H), 3.36 (s, 6H), 2.50 (s, 4H)   ,  HRMS (ESI) m/z calcd for 
C12H16N6O4S2 372.0674 found 373.0751 [M+H]+. 
 
 
 
5-iodo-2-amino pyrimidine (2.9):- A solution of 1.02 g (10.72 
mmol) of 2-aminopyrimidine in 12 mL of water was treated with 1.36 
g (4.26 mmol) of mercuric acetate and the mixture was stirred for two 
minutes on the steam-bath. The initially formed yellow precipitate 
quickly turned to a thick white slurry which was treated with a solution 
of 1.63 g of molecular iodine, I2, (6.44 mmol) in 12 mL of hot dioxane 
at 50 oC. All of the iodine reacted during 30 minutes of stirring during 
which time considerable evaporation was observed. The thick slurry 
was poured into several volumes of 15% potassium iodide solution and 
washed on the filter with fresh iodine solution until white. 
Recrystallization from absolute methanol gave pure compound, 2-
amino-5-iodopyrimidine 2.9 as an off-white solid (2.07 g, 87.3 %). 1H 
NMR (DPX 250 MHz, DMSO-d6) δ 8.35 (s, 2H), 6.83 (s, 2H); 13C NMR 
(DPX 250 MHz, DMSO-d6)  δ 172.04, 162.53, 98.25; HRMS (ESI) m/z 
calcd for C4H4IN3 220.9450, found [M+H] + 221.9517, mp 222.9 oC. 
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Di-tert-butyl (5-iodopyrimidin-2-yl)dicarbamate (2.10): To a 
stirred solution of 5-iodo-2-aminopyrimidine 2.9 (0.50 g, 2.3 mmol) in 
DMF (15 mL) were added di-tert-butyl dicarbonate (1.15 g, 5.27 
mmol) and 4-dimethylaminopyridine (0.025 g, 0.11 mmol) at room 
temperature. Progress of the reaction was monitored by thin layer 
chromatography using EtOAc/Hexane (50:50) as mobile phase on 
silica coated TLC plates. Upon completion of the reaction, DMF was 
evaporated under reduced pressure. Crude product obtained was 
subjected to flash chromatography on silica gel using EtOAc/Hexane 
(50:50) as eluent to give a pure iodide 2.10 as a colorless solid 
(0.652g, 68.4 %). 1H NMR (DPX 250 MHz, CDCl3) δ 8.84 (s, 2H), 1.40 
(s, 18H); 13C NMR (DPX 250 MHz, CDCl3)  δ 164.09, 157.46, 150.40, 
89.83, 83.91, 27.85; LCMS (ESI) m/z calcd for C14H20IN3O4, 421.049 
found 444.0, [M+H]+, mp 146.5 oC. 
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(5-{2-[Methanesulfonyl-(4-methoxy-benzyl)-amino]-
pyrimidin-5-ylethynyl}-pyrimidin-2-yl)-di-carbamic acid di-
tert-butyl ester (2.11):- To a three necked round bottomed flask 
were added alkyne 2.5 (0.500 g, 1.57 mmol), iodide 2.10 (0.69 g, 1.6 
mmol), CuI (0.015 g, 0.078 mmol), PPh3 (0.041 g, 0.15 mmol), 
Pd(PPh3)4 (0.018 g, 0.015 mmol) and TEA (2 mL) followed by 30 mL of 
dry acetonitrile.  The solution was brought to 60 oC. Upon completion 
of the reaction, in 10 hours, the solvent was evaporated under vacuo. 
The crude was subjected to the flash chromatography on silica gel 
using EtOAc/Hexane (2:8) as eluent to give pure alkyne 2.11 as a 
white solid (0.78 g, 82 %). 1H NMR (DPX 250 MHz, CDCl3) δ 3.59 (s, 
3H), 3.19 (s, 3H), 1.30 (s, 18H);  HRMS (ESI) m/z calcd for 
C29H34N6O7S 610.2209 found 633.2125 [M+Na]+, mp 83.2 oC. 
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N-{5-[2-(2-Amino-pyrimidin-5-yl)-ethyl]-pyrimidin-2-yl}-N-(4-
methoxy-benzyl)-methanesulfonamide (2.13):- To a solution of 
compound 2.11 (0.295 g, 0.48 mmol) in ethanol was added 10 wt% 
Pd/C catalyst and the resultant heterogeneous solution is subjected to 
hydrogenation as described in the synthesis of 2.7 except using 
ethanol as solvent. The obtained product 2.12 was taken in acetonitrile 
without further purification and Montmorillonite K-10 clay (0.3 g) was 
added carefully. The reaction was refluxed at 82 oC overnight. The 
resulting solution was filtered carefully over Celite and the Celite cake 
was washed with ethyl acetate (25 mL). The organic filtrate was 
subjected to rotary evaporation to obtain pure product 2.13 as a white 
solid, needing no further purification, in near quantitative yields. 1H 
NMR (DPX 250 MHz, CDCl3) δ 8.31 (s, 2H), 8.04 (s, 2H), 7.26 (d, 2H, 
J=7.50), 6.74 (d, 2H, J=7.50), 5.25 (s, 2H), 5.03 (s, 2H), 3.70 (s, 
3H), 3.27 (s, 3H), 2.71 (m, 4H).  
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N-{5-[2-(2-methanesulfonylamino-pyrimidin-5-yl)-ethyl]-
pyrimidin-2-yl}-chloromethanesulfonamide (2.15): To a stirred 
solution of aryl amine 2.13 (0.16 g, 0.38 mmol) in pyridine (15 mL) at 
room temperature was added to chloromethanesulfonyl chloride 
dropwise over a period of 10 minutes. Progress of the reaction was 
monitored by thin layer chromatography using MeOH/EtOAc (2:8) as 
eluent. Upon completion of the reaction solvent was removed under 
reduced pressure to give crude compound which on flash 
chromatography gave pure product 2.14 as an off-white solid which 
was taken to deprotection. HRMS (ESI) m/z calcd for C20H23ClN6O5S2 
526.0859 found 527.0939 [M+H]+. 
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PMB protected amine 2.14 was taken in round bottomed flask and 
cooled to 0 oC in an ice bath followed by the addition of neat TFA (5 
mL). The resulting solution was stirred at room temperature for 2 
hours. Upon completion of the reaction the solvent was removed under 
reduced pressure and the residue obtained was dissolved in DCM and 
subjected to rotary evaporation to azeotropically remove the residual 
trifluoroacetic acid (3×15 mL). The crude product obtained was 
precipitated using diethyl ether to get pure compound 2.15 as an off-
white solid. (0.057g, 36.5%) 1H NMR (DPX 250 MHz, DMSO-d6) 8.6 (s, 
2H), 8.3 (s, 1H), 8.1 (s, 2H), 4.1 (s, 3H), 2.9-2.6 (m, 4H), 2.1 (s, 3H), 
HRMS (ESI) m/z calcd for 406.0285 C12H15ClN6O4S2 found 407.0489 
[M+H]+.  
 
 
 
2-N(chloromethanesulfonyl)-aminopyrimidine (2.16): To a 
stirred solution of 2-aminopyrimidine (2.00 g, 21.0 mmol) in pyridine 
(25 mL) was added chloromethanesulfonyl chloride (3.29 g, 22.08 
mmol) over a period of ten minutes. Progress of the reaction was 
monitored by TLC (10% MeOH, 90% EtOAc). Upon completion of the 
53 
 
reaction, solvent was evaporated under reduced pressure and the 
residue was taken in methanol and evaporated to azeotropically 
remove traces of pyridine. The same was repeated three times with 20 
mL methanol each time. The crude product was subjected to flash 
column chromatography on silica gel using 1:9 MeOH/EtOAc as eluent 
to get a pure off-white solid 2.16 (2.73 g, 62.8 %). 1H NMR (Inova 
400 MHz, CDCl3) δ 12.11 (s, 1H), 8.61 (d, J=12.63), 7.14 (t, 1H, 
J=12.63), 5.28 (s, 2H); 13C NMR (Inova 400 MHz, CDCl3) δ 159.25, 
157.39, 116.16, 56.06; HRMS (ESI) m/z calcd for C5H6ClN3O2S 
206.9869, found 207.9952, [M+H]+ 229.9770 [M+Na]+.  
 
 
 
N-(5-iodo-pyrimidin-2-yl)-chloromethanesulfonamide (2.17): 
Same procedure as followed for the synthesis of 2.2 to get pure iodide 
2.17 as an off white solid in good yields (86%). 1H NMR (DPX 250 MHz, 
CDCl3) δ 8.77 (s, 2H), 7.36 (s, 1H), 5.44 (s, 2H). 
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N-Benzyl-N-(5-iodo-pyrimidin-2-yl)-chloromethanesulfonamide 
(2.18):- To a stirred solution of above iodide 2.17 (2.0 g, 6.69 mmol), 
KI (0.11 g, 0.67 mmol) and potassium carbonate (1.85 g, 13.38 
mmol) in 50 mL of dry DMF under nitrogen atmosphere was added 
benzyl bromide at room temperature. Upon completion of the reaction, 
solvent was evaporated under vacuo and the residue was dissolved in 
ethyl acetate (80 mL) and the same is washed with water (2×15 mL) 
and brine (2×15 mL), successively. Organic layer was dried over 
anhydrous sodium sulfate and the solvent was evaporated under 
vacuo. The crude was subjected to the flash chromatography on silica 
gel using EtOAc/Hexane (2:8) as eluent to give pure compound 2.18 
as a colorless liquid (81% yield). 1H NMR (DPX 250 MHz, CDCl3) δ 8.71 
(s, 2H), 7.3 (m, 5H), 5.3 (s, 2H), 3.34 (s, 3H);   13C NMR (DPX 250 
MHz, CDCl3) δ 163.02, 162.99, 137.05, 127.86, 127.66, 84.13, 49.39, 
42.92.  
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L-Serine methyl ester hydrochloride (2.19): To a stirred slurry of 
L-serine (15.0 g, 143 mmol) in 100 mL of methanol was added SOCl2 
(12 mL) at 0 oC over a period of 1 hr. The resulting clear solution was 
left to come to room temperature and continued stirring for another 20 
hrs before concentrating under reduced pressure. Excess HCl was 
azeotropically removed using methanol (3×60 mL) The compound 
obtained was dried under high vacuum overnight to give pure product 
L-Serine methyl ester hydrochloride 2.19 as white solid (22.0 g, ~ 
quantitative yields) 1H NMR (DPX 250 MHz, DMSO-d6)  δ 8.60 (s, 3H), 
5.63 (s, 1H), 4.07 (t, 1H), 3.82 (d, 2H), 3.72 (s, 3H); 13C NMR (DPX 
250 MHz, DMSO-d6) δ 168.43, 59.37, 54.32, 52.71.  
 
 
 
N-(tert-butoxycarbonyl)-L-serine methyl ester (2.20):- To an ice 
cold solution of ester 2.19 (22g, 142 mmol) in THF:H2O (3:1, 100 mL) 
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was added potassium carbonate (20.8g, 150 mmol) followed by Di tert 
butyl dicarbonate (35.9 g, 164.5 mmol). The resulting reaction was 
stirred vigorously for 23 hrs at room temperature. Upon completion 
the reaction mixture was concentrated under reduced pressure and the 
obtained crude was extracted into ethyl acetate (3×75 mL) from 
saturated brine solution. Organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The obtained crude 
was flash chromatographed on short column to get pure product N-
(tert-butoxycarbonyl)-L-serine methyl ester 2.20 as colorless viscous 
oil. (30.76 g, 98.8% yield). 1H NMR (DPX 250 MHz, CDCl3) δ 5.72 (d, 
1H), 4.49 (s, 1H), 4.04 (d, 2H), 3.91 (s, 3H), 3.19 (s, 1H), 1.58 (s, 
9H); 13C NMR (DPX 250 MHz, CDCl3) δ 171.49, 155.80, 80.32, 55.69, 
52.65, 28.28; LCMS (ESI) m/z calcd for C9H17NO5 219.11, found 242.1 
[M+Na]+. 
 
 
 
N-(tert butoxycarbonyl)-O-(p-toluenesulfonyl)-L-serine methyl 
ester (2.21):- To an ice cold solution of N-(tert-butoxycarbonyl)-L-
serine methyl ester 2.20 (1.4g, 6.38 mmol) in dry DCM (50 mL) were 
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added 4-dimethylaminopyridine (0.073g, 0.6 mmol) 4-toluene sulfonyl 
chloride (1.22g, 6.38 mmol) and triethylamine (0.64 g, 6.38 mmol) 
successively The reaction was monitored for the progress by thin layer 
chromatography. After completion of reaction the reaction mixture was 
concentrated under reduced pressure and the crude was dissolved in 
DCM and washed with brine solution. Organic layers were mixed and 
dried over Na2SO4 before flash chromatography to get pure compound, 
N-(tert butoxycarbonyl)-O-(p-toluenesulfonyl)-L-serine methyl ester 
2.21 1.66g (69.6 %). 1H NMR (DPX 250 MHz, CDCl3)  δ 7.7 (d, 2H, 
J=8.0), 7.3 (d, 2H, J=8.0), 5.2 (d, 1H, J=8.0), 4.5-4.1 (m, 2H), 3.62 
(s, 3H), 2.38 (s, 3H), 1.35 (s, 9H); 13C NMR (DPX 250 MHz, CDCl3) δ 
168.98, 145.16, 132.37, 129.96, 128.03, 52.97, 28.12, 21.44.  
 
 
 
 
N-(tert-Butoxycarbonyl)-β-iodoalanine methyl ester (2.22):  To 
a solution of N-(tert butoxycarbonyl)-O-(p-toluenesulfonyl)-L-serine 
methyl ester 2.21 (0.87 g, 2.34 mmol) in acetone (25 mL) was 
charged NaI (0.53g, 3.52 mmol) under stirring at room temperature. 
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The resulting solution was stirred at same temperature for 10 hrs 
before concentrating under reduced pressure. The crude product 
obtained was subjected to flash chromatography on silica gel column 
using EtOAc: Hexane (1:9) as eluent to get pure product N-(tert-
butoxycarbonyl)-β-iodoalanine methyl ester 2.22 as colorless viscous 
liquid (0.58g, 75.0%)  
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 CHAPTER THREE 
SYNTHESIS OF α–ARYL α, β-EPOXY CARBOXYLATES, 
PHOSPHONATES AND THEIR BIOLOGICAL ACTIVITY AGAINST 
TYROSINE PHOSPHATASES  
3.1. General introduction 
 
Carboxylates are a very important class of compounds to both 
biologists and chemists as they play some very significant roles in 
biology. One important class of compounds with carboxylic acid 
functional group is amino acids which are indispensable to the living 
organism whether they are primitive organisms or advanced 
organisms.1,2  2-Hydroxypropanoic acid also known as lactic acid plays 
a role in several biochemical processes and was first isolated in 1780 
by Swedish chemist Carl Wilhelm Scheele. In animals, it is produced 
from another carboxylic acid peruvate constantly.3 (Figure 3.1). 
Similarly, phosphates are also very significant as they play very crucial 
roles in the biology as in the formation of adenosine tri-phosphate 
from adenosine di-phosphate and the phosphorylation of most of the 
enzymes to get into the right 3D conformation so as to perform the 
assigned function in the body.4  
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 Figure 3.1 Conversion of pyruvate to lactate in respiratory cycle 
 
Our current interest is to synthesize phosphonates and 
carboxylates as phosphate mimics of both epoxy and aziridine 
derivatives and test their activities to develop the inhibitors for 
tyrosine phosphatases mainly concentrating on SHP-2 and PTP1B 
which has been briefly explained in chapter one. Some of the 
important carboxylates which were tested for activity against PTP1B 
were shown in Figure 3.2. Ertiprotafib of Wyeth-Ayerst reached clinical 
trials and failed to go further because of efficacy issues.5 
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 Figure 3.2 Some of the phosphatase inhibitors with carboxy 
functionality6 
 
3.2. Phosphonates as tyrosine phosphatase inhibitors 
Synthesis of phosphonate ester 3.4 was discussed and the 
activity is explained in the following sections of this chapter. 
3.3. Carboxylates as tyrosine phosphatase inhibitors 
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Synthesis of carboxylates was discussed and the activity is 
explained in the following sections of this chapter. 
 
3.4. Results and discussion 
3.4.1 Synthesis of α-aryl α,β-epoxy phosphonates 
 
Synthesis of the phosphonates started from commercially 
available benzoyl chloride which was reacted with triethyl phosphite to 
form α-keto phosphonate ester 3.2. Phosphonate 3.2 was epoxidized 
with trimethyl sulphonium iodide prepared in our lab to get α,β-epoxy 
phosphonate ester 3.3 in good yields. Epoxy phosphonate was 
subjected to mono deprotection with LiBr in 4-methyl-2-pentanone at 
80 oC to get compound 3.4 in good yields.7 (Scheme 3.1) 
 
Scheme 3.1 Synthesis of α,β-epoxy phosphonate 3.4 
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The direct di-deprotection of 3.3 failed to give the desired 
phosphonic acid by using the same conditions at higher temperatures. 
The mono deprotected compound starts to precipitate as lithium salt 
3.4 and so does not give the product. We then converted the di alkyl 
phosphonate to di silyl phosphonate 3.5 using trimethyl silyl chloride 
(TMSCl) in dichloromethane as solvent which can be easily hydrolyzed 
to the corresponding epoxy phosphonic acid 3.6 or tested without 
deprotection as it can get deprotected at physiological conditions.8  
 
Scheme 3.2 Synthesis of α,β-epoxy phosphonic acid 3.6 
3.4.2. Synthesis of α-aryl-α,β-epoxy carboxylates 
 
Synthesis of carboxylates started from the commercially 
available aromatic aldehydes and alpha phenyl methyl acetate. Alpha 
phenyl methyl acetate was converted to diaza ester 3.7 employing 
diazo transfer reaction with p-ABSA as diaza transfer reagent and DBU 
as base in excellent yields.9 Diazo-ester 3.7 was reacted with various 
in house aldehydes to get α,β-epoxy carboxylates in very good yields. 
The product with benzaldehyde was trans as reported in literature.10 
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We selected aromatic aldehydes with various electron donating, 
electron withdrawing and alkyl, halo and alkoxy groups so that we can 
study the effects of substituents on the activity against selected 
phosphatases. 
 
Scheme 3.3 Synthesis of α,β-epoxy α-aryl carboxylates 3.9a-g 
 
The methyl ester was deprotected using standard conditions with 
LiOH as base in THF: H2O mixture to get carboxylic acid 3.9 in 
excellent yields.  
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Compound 3.9a was also prepared by using n-BuLi/TMEDA/CO2 
reagents from (trans)-1,2-Di-phenyl oxirane to see if it gives 
exclusively trans product (Boxed in Scheme 3.5). The same conditions 
with formaldehyde and its equivalents did not give the desired product 
3.8h as shown in Scheme 3.4 instead gave the dimerized derivative of 
diazo-ester 3.8i which was confirmed using NMR techniques as well as 
crystal structure studies.11 The directed lithiation with BuLi/TMEDA and 
subsequent reaction with CO2 as electrophile were not reported 
anywhere in the literature to the best of our knowledge. Whereas 
different electrophiles like alkyl iodides give the corresponding 
derivatives in excellent yields and were reported in literature.12 
 
 
Scheme 3.4 Failed attempts to synthesis epoxy carboxylates with 
methanal equivalents 
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3.4.3 Synthesis of α,β-aziridino carboxylates 
The results of directed lithiation on epoxide 3.10 and trapping 
with carbon dioxide prompted us to apply the same methodology to 
make aziridine derivatives. For this approach, trans-stilbene was 
epoxidized using m-CPBA as epoxidizing agent in chloroform at 0 oC to 
get trans-epoxide 3.10 in very good yields. The epoxide was cleaved 
to get trans-azido alcohol 3.11 using sodium azide and ammonium 
chloride as reported in the literature. The azido alcohol was refluxed in 
acetonitrile in the presence of triphenylphosphine to obtain aziridine 
3.12 in excellent yields.13 The attempted directed lithiation with n-
BuLi/TMEDA followed by reaction with carbon dioxide did not give any 
desired product. Changing n-BuLi with s-BuLi and t-BuLi did not 
improve the results. Thus, we changed the strategy and the free NH 
group was protected as the Boc derivative using di-tert-butoxy 
anhydride in the presence of DMAP in dichloromethane as solvent gave 
excellent yields of aziridine 3.13.14 The product was then subjected to 
the same directed lithiation conditions but we were only able to run 
mass spectral analysis as the yields were dismal. (Scheme 3.5) 
73 
 
 Scheme 3.5 Synthesis of α,β-aziridino carboxylate 3.14 
This led us to apply the same Rhodium catalyzed reaction 
conditions applied above in making carboxylates 3.8a-g. For this, we 
needed imines with suitable groups on amine so that it is easy to 
remove after the insertion reaction, which will be explained in this 
report shortly.  
Benzaldehyde was reacted with 40% methylamine in water at 0 
oC to get N-methyl imine 3.16 in excellent yields.15 The reaction with 
4-methoxybenzylamine in presence of anhydrous sodium sulfate in 
dichloromethane at room temperature gave very good yields of imine 
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3.17. The rhodium catalyzed insertion reaction with diazo-ester 3.17 
did not give the desired product and we could not find any reason 
behind this. To find out if the free NH group is having any effect on the 
reaction conditions we attempted the same reaction conditions on 
styrene and the reaction worked perfectly to give 3.21 in very good 
yields as reported in the literature. So the protecting group has been 
changed to benzyl and for that benzaldehyde was protected as imine 
3.18 and was subjected to obtain N-benzyl aziridine carboxylate 3.19 
in decent yields. The ester was subjected to base hydrolysis using 
excess lithium hydroxide in tetrahydrofuran and water mixture as 
solvent to get the corresponding carboxylic acid 3.20 in moderate 
isolated yields. (Scheme 3.7)16 
 
Scheme 3.6 Synthesis of N-alkyl α,β-aziridino carboxylate 3.19 
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 Scheme 3.7 Synthesis of N-benzyl aziridine carboxylate 3.20 
 
 
Scheme 3.8 Synthesis of α,β-diaryl α-cyclopropane carboxylate 
3.5. Biological activity studies 
IC50 was defined as the concentration of compound that caused a 
decrease of 50% in magnitude in the PTP activity. 2-Aminopyrimidine 
chlorides, sulfonamides and α-aryl, α,β-epoxy carboxylates and 
phosphates synthesized were tested for activity of inhibition for IC50 
using a human recombinant GST-Shp-2 PTP domain protein. 6,8-
Difluoro-4-methylumbelliferyl phosphate (DiFMUP) was used as the 
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substrate. Testing was performed in duplicates at room temperature in 
black, half area 96-well plates. Incubation was carried out at room 
temperature for 20 min in a 75 µL reaction mixture containing 25 mM 
Hepes, pH 7.0, 50 mM NaCl, 1 mM DTT, 0.01% Triton X-100, 40 µM 
DiFMUP, 3% DMSO or compound. Fluorescent signal was measured at 
excitation and emission wavelengths of 355 nm and 460 nm 
respectively. For IC50 determination, eight concentrations of each 
compound at one third dilutions were tested. The ranges of compound 
concentrations used in PTP assay were determined from preliminary 
trials. According to the results obtained epoxy carboxylates exhibited 
good inhibitory activity among the compounds synthesized. 
Preliminary results show that these compounds work as noncovalent 
inhibitors.  
Compounds 3.9d and 3.9c showed activity against Shp-2 protein 
phosphatase with IC50 values 5.6 mM and 20.8 mM respectively. Epoxy 
carboxylate 3.9a without any aromatic substitutions showed good 
activity against the same target with IC50 value of 0.0069 mM (6.9 
µM).  
3.6. Conclusion and future directions 
Synthesis of some epoxy and aziridino carboxylates and 
phosphonates was performed and some of them were tested against 
PTPs and we were excited by some of relatively promising inhibitors 
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against SHP-2 phosphatase. The obtained compounds can be modified 
by using the same methodology mentioned in chapter-2 of this writing 
to make amino acid derivatives of the same carboxylates and put into 
small peptides which can increase the selectivity many times. 
Compound 3.9a shows good activity against Shp-2 phosphatase and 
this kind of epoxy esters are more stable than the simple epoxides and 
it is interesting to see if the activity can be increased simultaneously 
by substituting with pyrimidine units and making the second 
generation compounds. It can be put into small peptides and can be 
more selective at the same time more active against Shp-2 
phosphatase. 
3.7 Experimental Procedures 
Diethyl-(phenylcarbonyl)-phosphonate (3.2)  
 
 
 
To an ice cold solution of benzoyl chloride (4.0 g, 28.4 mmol) in 25 mL 
of dichloromethane was added triethyl phosphite (4.7 g, 28.4 mmol) 
dropwise. Reaction was left to come to room temperature and stirred 
for a further 12 hours. After the complete consumption of starting 
material, 50 mL of dichloromethane was added, and the organic layer 
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was washed with saturated sodium bicarbonate solution (3×15 mL) 
followed by saturated brine solution (3×15 mL). The extract was dried 
over anhydrous MgSO4 and evaporated in vacuo. The residue was 
purified by column chromatography on silica gel using EtOAc/Hexanes 
(1:9) as eluent to give the pure product 3.2 as a greenish yellow 
liquid. (4.9 g, 72 %). 1H NMR (DPX 250 MHz, CDCl3) δ 8.3 (m, 2H), 7.6 
(t, 1H), 7.5 (m, 2H), 4.3 (q, 4H), 1.4 (t, 6H);  13C NMR (DPX 250 MHz, 
CDCl3) δ 200.4, 136.0, 134.7, 129.8, 128.8, 63.9, 16.3; HRMS (ESI) 
m/z calcd for C11H15O4P is 242.070 found 243.078 [M+H]+. 
Phosphonic acid, (2-phenyloxiranyl)-, diethyl ester (3.3) 
 
 
 
A solution of triphenylphosphine methyl bromide (1.55 g, 4.33 mmol) 
and DIEA (57 µL, 0.41 mmol) in THF (15 mL) was cooled to -76 oC 
before adding n-BuLi dropwise. After briefly stirring at -76 oC for about 
15 minutes, the reaction was brought to room temperature and further 
stirred for an hour before cooling back to -76 oC at which temperature, 
the phosphate ester (1.0 g, 4.13 mmol) was added. The reaction was 
left to come to room temperature and further stirred for 15 hours 
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before quenching with 1N HCl solution at ice cold temperature. The 
product was extracted into diethyl ether (3×25 mL). All organic layers 
were combined and washed with brine solution (3×15 mL) and dried 
over anhydrous Na2SO4 and evaporated under reduced pressure to get 
crude product which on subjecting to flash column chromatography 
gave pure product 3.3 as colorless liquid (0.66 g, 67 %).1H NMR (DPX 
250 MHz, CDCl3) δ 7.9-7.3 (m, 5H), 4.0 (q, 4H), 1.25 (t, 6H); 13C NMR 
(DPX 250 MHz, CDCl3) δ  152.25, 134.37, 129.10, 128.40, 125.21, 
97.32, 64.59, 16.07; HRMS (ESI) m/z calcd for C12H17O4P is 256.0864, 
found 257.0 [M+H]+ 
(2-Phenyl-oxiranyl)-lithium phosphonate mono-ethyl ester 
(3.4) 
 
 
 
To a solution of diethyl phosphonate 3.3 (0.1 g, 0.39 mmol) in 4-
methyl-2-pentanone (5 mL), lithium bromide (0.034 g, 0.39 mmol), 
was added and the mixture was stirred at 70 oC. After a few minutes 
lithium bromide dissolved and a white precipitate started to 
precipitate. Heating was continued for about 2 hours. The solvent was 
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removed under vacuo and ether (20 mL) was added to the residue. 
The product was collected by filtration and washed with another 10 mL 
of ether. No further purification was needed as the compound was 
pure on TLC and NMR studies. The pure compound 3.4 was obtained 
as white solid. (0.05 g, 48%).1H NMR (DPX 250 MHz, CDCl3) δ 7.39-
7.24 (m, 5H), 5.0 (d, 2H), 3.7 (q, 2H, J=7.50), 2.5 (s, 1H), 1.2 (t, 3H, 
J=7.5); 13C NMR (DPX 250 MHz, CDCl3) δ 153.13, 137.10, 127.95, 
127.82, 124.83, 92.74, 59.99, 16.57 ; HRMS (ESI) m/z calcd for 
C10H13O4P is 228.055, found 227.01 [M-H]-.  
Diazo-phenyl-acetic acid methyl ester (3.7):  
 
 
 
To a stirred solution of 4-acetamidobenzenesulfonyl azide (p-
ABSA, 24.8 g, 20.0 mmol) in 45 mL of dry acetonitrile was charged 
with methyl phenyl acetate (2.5 g, 17 mmol) followed by the dropwise 
addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 3.55 g, 23.3 
mmol) at ambient temperatures. Reaction mixture gradually turned 
into reddish from yellow. After the completion of the reaction by TLC, 
in about 8 hours, the reaction was diluted with 20 mL of water. 
Product was extracted with ether (3×15 mL). Organic fractions were 
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combined and washed with 10% sodium bicarbonate solution (3×10 
mL), followed by saturated brine solution (3×10 mL). Organic layer 
was dried over anhydrous sodium sulfate before evaporating under 
reduced pressure to give crude product. Flash chromatography on 
silica gel using EtOAc/Hexane (1:9) as eluent afforded pure diaza ester 
3.7 as a red liquid (2.69 g, 93%). 1H NMR (DPX 250 MHz, CDCl3) δ 
7.4-7.3 (m, 2H), 7.3-7.2 (m, 2H), 7.1-7.0 (1H), 3.75 (s, 3H); 13C NMR 
(DPX 250 MHz, CDCl3) δ 165.58, 129.29, 128.6, 127.13, 125.50, 
123.95, 52.04. 
General Procedure for Rh2(OAc)4 catalyzed carbene insertion 
reaction:  
 
 
 
To a flame dried 100 mL 3 necked round bottom flask, Rh2(OAc)4 was 
charged under nitrogen flow. To the same freshly distilled 
dichloromethane was charged followed by the addition of aldehyde. 
The resulting solution was brought to 45 oC and a solution of diazo 
ester 3.7 in dry dichloromethane was added over a period of 1.5 
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hours. The reaction was monitored for the progress by thin layer 
chromatography. After the disappearance of the aldehyde the reaction 
was brought to ambient temperatures and the reaction mixture was 
filtered through Celite and the same was concentrated under reduced 
pressure. The crude product obtained was subjected to flash column 
chromatography on silica gel to get corresponding epoxy carboxylates 
(racemic) 3.8a-g in pure form. (TLC solvent 30% EtOAc in 70% 
Hexane) 
 
2,3-diphenyl-oxirane-2-carboxylic acid methyl ester (3.8a) 
colorless solid, 88% yield  1H NMR (DPX 250 MHz, CDCl3) δ 7.6 (m, 
2H), 7.4-7.3 (m, 8H), 4.1 (s, 1H), 3.5 (s, 3H); 13C (DPX 250 MHz, 
CDCl3) δ 167.2, 134.7, 133.7, 128.9, 128.7, 128.6, 128.4, 126.2, 
126.0, 67.1, 65.9, 52.3. 
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3-(4-chloro-phenyl)-2-phenyl-oxirane-2-carboxylic acid methyl 
ester (3.8b) white solid, 67% yield. 1H NMR (DPX 250 MHz, CDCl3) δ 
7.6-7.5 (m, 2H), 7.35-7.30 (m, 3H), 7.25-7.2 (m, 4H), 4.04 (s, 1H), 
3.49 (s, 3H) 
 
3-(4-bromo-phenyl)-2-phenyl-oxirane-2-carboxylic acid methyl 
ester (3.8c) white solid, 91% yield. 1H NMR (DPX 250 MHz, CDCl3) δ 
7.9 (d, 2H), 7.7 (d, 2H), 7.4-7.2 (m, 5H), 4.2 (s, 1H), 3.7 (s, 3H), 3.6 
(s, 3H); LCMS (ESI) m/z calcd for C16H13BrO3 is 332.0, found 332.9 & 
334.9 [M+2+H]+ 
 
3-(4-methoxy-phenyl)-2-phenyl-oxirane-2-carboxylic acid 
methyl ester (3.8d) white solid, 86% yield. 1H NMR (DPX 250 MHz, 
CDCl3) δ 7.63 (d, 2H), 7.40-7.25 (m, 5H), 6.95-6.85 (d, 2H), 4.08 (s, 
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1H), 3.78 (s, 3H), 3.56 (s, 3H); HRMS (ESI) m/z calcd for C17H16O4 is 
284.10, found 285.1 [M+H]+. 
 
3-(4-nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid methyl 
ester (3.8e) yellowish solid, 63% yield. 1H NMR (DPX 250 MHz, 
CDCl3) δ 8.4 (d, 2H), 8.1 (d, 2H), 7.8-7.1 (m, 5H), 4.1 (s, 1H), 3.4 (s, 
3H); 13C (DPX 250 MHz, CDCl3) δ 165.3, 134.2, 130.6, 129.2, 128.5, 
127.1, 126.9, 124.7, 124.5, 66.4, 63.3, 52.4,; HRMS (ESI) m/z calcd 
for C16H13NO5 is 300.08, found 317.11 [M+NH4]+ 
  
 
 
3-(2-methoxy-phenyl)-2-phenyl-oxirane-2-carboxylic acid 
methyl ester (3.8f) colorless solid, 87% yield. 1H NMR (DPX 250 
MHz, CDCl3) δ 7.6 (m, 2H), 7.45-7.25 (m, 4H), 6.95-6.75 (m, 3H), 
4.32 (s, 1H), 3.73 (s, 3H), 3.40 (s, 3H); HRMS (ESI) m/z calcd for 
C16H17O4 is 284.10, found 285.10 [M+H]+ 
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3-(2-nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid methyl 
ester (3.8g) yellowish solid, 72% yield. 1H NMR (DPX 250 MHz, 
CDCl3) δ 8.2-8.1 (d, 1H), 7.8-7.6 (m, 4H), 7.4-7.2 (m, 4H), 4.6 (s, 
1H), 3.3 (s, 3H); HRMS (ESI) m/z calcd for C16H13NO5 is 299.07, found 
300.08 [M+H]+, 317.11 [M+NH4]+  
General procedure for the deprotection of methyl ester to 
carboxylic acid:- 
 
 
 
To a solution of α,β-epoxy methyl carboxylate 3.8a-g in 
tetrahydrofuran-water mixture (~1:1) was added excess LiOH solution 
86 
 
(1N) at 0 oC under stirring. Progress of the deprotection was 
monitored by thin layer chromatography. Upon completion of the 
deprotection the reaction mixture was subjected to rotary evaporation 
to remove organic solvent. The resulting basic solution was washed 
with ethyl acetate to remove any unreacted ester and the aqueous 
layer was cooled in an ice bath before neutralizing to pH ~7.0. The 
same was extracted into ethyl acetate (3×40 mL) and the organic 
portions were combined together and dried over anhydrous Na2SO4 
before concentrating under reduced pressure. The product was pure 
enough most of the times but needed to do flash column 
chromatography to get the corresponding carboxylic acid 3.9a-g 
(racemic). (TLC solvent 10% MeOH in 90% EtOAc)  
 
 
2,3-diphenyl-oxirane-2-carboxylic acid (3.9a) white solid, 76% 
yield. 1H NMR (DPX 250 MHz, CDCl3) δ 11.9 (s, 1H), 7.6 (m, 2H), 7.4-
7.3 (m, 3H), 4.0 (s, 1H); HRMS (ESI) m/z calcd for C15H12O3 is 
240.08, found 241.09 [M+H]+. 
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 3-(4-chloro-phenyl)-2-phenyl-oxirane-2-carboxylic acid (3.9b) 
off-white solid, 80% yield. 13C NMR (DPX 250 MHz, CDCl3) δ 181.9, 
137.8, 134.9, 132.1, 128.6, 127.8, 127.6, 127.3, 126.3; HRMS (ESI) 
m/z calcd for C15H11ClO3 is 274.04, found 275.04 [M+H]+. 
 
  
3-(4-bromo-phenyl)-2-phenyl-oxirane-2-carboxylic acid (3.9c) 
white solid 81% yield. 1H NMR (DPX 250 MHz, CDCl3) δ 7.45-7.35 (m, 
4H), 7.6-7.5 (m, 3H), 7.3-7.2 (m, 2H), 4.4 (s, 1H), 3.3 (bs, 1H); 13C-
NMR 177.96, 133.69, 131.69, 129.41, 129.17, 128.70, 127.90, 
127.44, 126.40, 65.48, 40.98.; HRMS (ESI) m/z calcd for C15H11BrO3 
is 317.9, found 318.9 [M+H]+   
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3-(4-methoxy-phenyl)-2-phenyl-oxirane-2-carboxylic acid 
(3.9d) white solid, 58% yield. HRMS (ESI) m/z calcd for C16H14O4 is 
270.09, found 271.09 [M+H]+.  
 
3-(4-nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid (3.9e) 
yellow solid, 62% yield. HRMS (ESI) m/z calcd for C15H11NO5 is 
285.06, found 286.07 [M+H]+. 
 
 
3-(2-methoxy-phenyl)-2-phenyl-oxirane-2-carboxylic acid 
(3.9f) white solid, 66% yield. HRMS (ESI) m/z calcd for C16H14O4 is 
270.09, found 271.09 [M+H]+. 
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3-(2-nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid (3.9g) 
brown solid, 74.3% yield, 1H NMR (DPX 250 MHz, DMSO-d6) δ 8.2-8.1 
(d, 1H), 7.8-7.6 (m, 4H), 7.4-7.2 (m, 3H), 7.6-7.5 (d, 1H), 4.4 (s, 
1H); HRMS (ESI) m/z calcd for C15H11NO5 is 285.06, found 286.07 
[M+H]+ 
 
2,3-diphenyloxirane (3.10) 
 
 
 
To an ice cold solution of m-CPBA (65%, 2.7 g, 10.20 mmol) in 
chloroform (30 mL) was added a solution of trans-stilbene (1.0 g, 5.55 
mmol) in chloroform (30 mL) over a period of 30 minutes. The 
reaction was left to come to ambient temperatures and stirred further 
until the starting material disappeared. The reaction mixture was 
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diluted with chloroform (40 mL) and the same was washed with 
saturated NaHCO3 (3×30 mL) and saturated brine solution (3×20 mL) 
successively and the organic layer was dried over anhydrous Na2SO4 
before concentrating to get crude product which on further purification 
by flash column chromatography gave pure epoxide 3.10 as thick 
colorless oil (0.73 g, 67.59%). 1H NMR (DPX 250 MHz, CDCl3) δ 7.47-
7.37 (m, 10H), 3.92 (s, 2H); 13C NMR (DPX 250 MHz, CDCl3) δ 137.1, 
128.6, 128.4, 125.6, 62.9; HRMS (ESI) m/z calcd for C14H12O is 
196.08, found 197.09.[M+H]+ 
β-azido-α-phenyl benzeneethanol (3.11) 
 
 
 
Trans-stilbene oxide 3.10 (1g, 5.11 mmol), sodium azide (0.76 g, 11. 
73 mmol), and NH4Cl were dissolved in 40 mL of MeOH: H2O (4:1). 
The resulting clear solution was refluxed for 2.5 hrs and then allowed 
to stir at room temperature for additional 8 hrs. Upon completion of 
the reaction by TLC dichloromethane and water (25 mL each) were 
added to the reaction mixture. The two layers were separated and the 
water layer was extracted with dichloromethane (2×25 mL). The 
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organic layers were combined and washed with saturated brine 
solution (2×25 mL) before drying over anhydrous MgSO4. Removal of 
solvent and further purification of the obtained crude by flash column 
chromatography gave pure azido-alcohol 3.11 as light yellow liquid 
(0.91 g, 74 %). 1H NMR (DPX 250 MHz, CDCl3) δ 7.3-7.2 (m, 10H), 4.8 
(dd, 1H, J12 = 3.00, J13 = 3.50), 4.7 (d, 1H, J=6.75), 2.3 (d, 1H, 
J=3.00); 13C NMR (DPX 250 MHz, CDCl3) δ 139.71, 136.01, 128.74, 
128.69, 128.41, 128.33, 128.11, 127.10, 77.00, 71.27.  
2,3-Diphenylaziridine (3.12) 
 
 
 
Azido-alcohol 3.11 (3.6 g, 15 mmol) and PPh3 (4.01 g, 15.3 mmol) 
were dissolved in acetonitrile (40 mL) under nitrogen atmosphere and 
heated to reflux for 2.5 hrs. Upon completion of the reaction the 
solvent was removed under reduced pressure and the resultant crude 
was purified by flash column chromatography to get pure aziridine 
3.12 as light yellow liquid (2.72 g, 92.6 %). 1H NMR (DPX 250 MHz, 
CDCl3) δ 7.32-7.12 (m, 10H), 3.00 (bs, 2H), 1.28 (bs, 1H, NH); 13C 
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NMR (DPX 250 MHz, CDCl3) δ 139.7, 128.7, 127.5, 125.5, 43.7; HRMS 
(ESI) m/z calcd for C14H13N is 195.1048 found 196.1185 [M+H]+ 
1-Aziridinecarboxylic acid,2,3-diphenyl-, 1,1-dimethylethyl 
ester (3.13) 
 
 
To a solution of aziridine 3.12 (0.50 g, 2.6 mmol) in dichloromethane 
(25 mL) at ice-cold temperature were added di-tert-butyl dicarbonate 
(0.67 g, 3.1 mmol) and DMAP (0.03 g, 0.25 mmol). Reaction was 
monitored for the progress by thin layer chromatography. Starting 
material completely disappeared in 40 minutes. Solvent was removed 
under reduced pressure and the crude was subjected to flash column 
chromatography to get pure compound as the colorless solid (0.69 g, 
91.7 %). 1H NMR (DPX 250 MHz, CDCl3) δ 7.53-7.47 (m, 10H), 3.92 
(s, 2H), 1.33 (s, 9H); 13C NMR (DPX 250 MHz, CDCl3) δ 159.41, 
135.55, 128.52, 128.12, 127.03, 81.47, 47.63, 27.66. 
2,3-diphenyl, 1-tert-butoxy carbonyl-2-aziridine carboxylic acid 
(3.14) 
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To a stirred solution of 1-tert-butoxy carbonyl-2-aziridine 3.13 in 
tetrahydrofuran was added TMEDA at -78 oC. To the above solution n-
BuLi was added and the solution stirred at the same temperature for 2 
hrs before adding dry ice. The reaction was brought to room 
temperature gradually and monitored for the progress by thin layer 
chromatography. No significant product was obtained even though 
HRMS and LCMS showed the presence of product. Repeated reactions 
with s-BuLi and t-BuLi did not result in any improvements.  
N-(phenylmethylene)-methanamine (3.16) 
 
 
A mixture of benzaldehyde (12.0 g, 113 mmol) and excess of 40% 
methane amine in water (16 mL, 192.0 mmol) was stirred at 0 oC for 2 
hrs and further stirred at ambient temperatures overnight. After the 
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completion of the reaction the product was extracted into ethyl acetate 
(3×50 mL). Organic layers were combined washed with brine solution 
(3×40 mL) and dried over anhydrous sodium sulfate. The solvent was 
removed under reduced pressure and further vacuum purified to get 
pure product 3.16 as liquid (13.45 g, 97%) 1H NMR (250 MHz, CDCl3) 
δ 8.25 (s, 1H), 7.75 (m, 2H), 7.45 (m, 3H); 13C NMR (250 MHz, CDCl3) 
δ 162.50, 136.28, 130.65, 128.64, 127.01, 40.29. 
Benzenemethanamine-4-methoxy-N-(phenylmethylene) (3.17) 
 
 
To a stirred solution of benzaldehyde (1.39 g, 13.1 mmol) and 4-
methoxy benzylamine (1.8 g, 57 mmol) in dichloromethane (30 mL) 
was added anhydrous Na2SO4 (1.6 g, 113 mmol) at ambient 
temperatures. Reaction was stirred at the same temperature for about 
12 hours before filtering the solids off and concentrating under 
reduced pressure. The crude product obtained was subjected to flash 
column chromatography to get pure compound 3.17 as a colorless 
liquid (2.36 g, 80.0%). 1H NMR (DPX 250 MHz, CDCl3) δ 8.21 (s, 2H), 
7.68-7.58 (m, 2H), 7.30-7.20 (m, 3H), 7.17-7.08, (d, 2H), 6.80-6.70 
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(d, 2H); 13C NMR (DPX 250 MHz, CDCl3) δ 192.44, 158.76, 136.30, 
131.46, 130.80, 129.81, 129.08, 128.68, 128.35, 64.59, 55.32. 
Benzyl-benzylidene-amine (3.18)  
 
 
 
Same procedure was followed as mentioned for 3.17 benzaldehyde 
(6.0 g, 57 mmol) and benzylamine (6.05 g, 56.5 mmol) in 
dichloromethane (100 mL) with anhydrous Na2SO4 (16.06 g, 113.1 
mmol). 3.18 is colorless liquid. (10.26 g, 92.93 %). 1H NMR (DPX 250 
MHz, CDCl3) δ 8.46 (s, 1H), 7.95-7.75 (m, 2H), 7.55-7.25 (m, 6H), 
4.90 (s, 2H); 13C (DPX 250 MHz, CDCl3) δ 162.08, 139.33, 136.18, 
130.84, 128.67, 128.56, 128.34, 128.04, 127.06, 65.10; LCMS (ESI) 
m/z calcd for C14H13N is 195.1048 found 196.10 [M+H]+. 
 
1-Benzyl-2,3-diphenyl-aziridine-2-carboxylicacid methyl ester 
(3.19)  
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 To a stirred solution of imine (0.886 g, 4.54 mmol) in dry 
dichloromethane (15 mL) was added Rh2(OAc)4 (0.02 g, 0.045 mmol) 
under nitrogen atmosphere and the reaction mixture was heated to 40 
oC. A solution of diazo ester 3.7 (0.80g, 4.54 mmol) in dry 
dichloromethane (10 mL) was added over a period of 40 minutes and 
the reaction was monitored for progress. After the completion, the 
reaction mixture was passed through Celite bed to remove rhodium 
salts. The solvent was removed and the crude was flash 
chromatographed to get pure compound as yellow solid. (0.426 g, 
30.3 %). 1H NMR (DPX 250 MHz, CDCl3) δ 7.75 (m, 3H), 7.65-7.15 
(m, 12H), 4.31 (s, 1H), 3.91 (s, 2H), 3.60 (s, 3H); 13C NMR (DPX 250 
MHz, CDCl3) δ 165.78, 139.47, 138.04, 132.20, 131.09, 128.89, 
128.77, 128.48, 128.37, 128.18, 128.06, 127.61, 127.20, 79.86, 
64.34, 52.29, 51.35.HRMS (ESI) m/z calcd for C23H21NO2 343.1572 
found 344.1626 [M+H]+. 
1-Benzyl-2,3-diphenyl-aziridine-2-carboxylicacid (3.20)  
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 Same procedure was used as mentioned for the hydrolysis of ester 
3.8a-g except increasing the THF ratio in the solvent mixture. 
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 CHAPTER FOUR 
TOWARDS THE SYNTHESIS OF CYSTEINE BASED PEPTIDE 
NUCLEIC ACIDS (CPNAs) AND HYBRIDS 
 
 
4.1 General introduction 
 
The genetic information of most organisms is encoded in the 
sequence of double stranded DNA (dsDNA), also known as the 
molecule of life, which is transcribed into mRNA during transcription. 
The blocking of transcription has become an attractive target for 
therapeutic discovery.1, 2 A variety of reagents, both synthetic and 
natural, are capable of interacting with DNA and (or) RNA made up off 
purines and pyrimidines (Figure 4.1a and 4.1b). These interactions 
may inactivate or completely destroy the nucleic acids. This means the 
unwanted or disease causing genes, responsible for the production of 
mutated proteins and ultimately leading to the production of 
dysfunctional proteins, can be repaired by utilizing the specific 
hydrogen bonding patterns between the base pairs. Specially designed 
short nucleic acid sequences or oligonucleotides can selectively bind to 
the targeted DNA or RNA.  
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Oligonucleotides that selectively bind to the DNA are termed 
‘antigene oligonucleotides’3 and the oligonucleotides that selectively 
bind to the RNA are called ‘antisense oligonucleotides’4. Peptide 
Nucleic Acids are hybrid structures with some special advantages.  
 
Figure 4.1a. DNA double helix structure-sugar phosphate backbone-
adenine-thymine, guanine-cytosine bases [courtesy: 
dearbornschools.org] 
 
Since the discovery of Peptide Nucleic Acids (PNAs) by Nielsen et 
al5-6 in 1991 they have attracted significant attention as promising 
candidates for the gene therapeutic7-11 drug discovery. PNAs have 
applications in therapeutic drug discovery, diagnosis12 and 
biosensing13. 
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 Figure 4.1b Purines and pyrimidines of nucleic acids, DNA and RNA 
PNAs are achiral, neutral, unnatural DNA analogs (Figure 4.2) in 
which the nucleobases are attached to the pseudo peptide backbone, 
made of repeated units of 2-aminoethylene glycine moieties, via 
methylenecarbonyl linkers. PNA’s are interesting pseudo peptides 
because of their remarkable affinity and specificity to hybridize with 
complimentary nucleic acids, and their resistance to chemical and 
biological reactions catalyzed by proteases and nucleases. These 
properties are due to their uncharged and flexible polyamide 
backbone. They mimic DNA and/or RNA by forming hetero duplexes 
with complimentary nucleic acids.  The complexes formed by the 
interaction of PNA with DNA and/or RNA generally show higher thermal 
stabilities than the complexes formed by the interaction of DNA with 
DNA or RNA. 
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 Figure 4.2. Structures of achiral PNA backbone and chiral DNA 
backbone 
 
The PNAs bind to the complimentary DNA and RNA sequences 
through Watson-Crick, and Hoogsteen in some cases, hydrogen 
bonding with higher affinity than the corresponding DNA or RNA 
sequences.  
 
Even though the peptide nucleic acids are considered as 
promising candidates for the gene therapeutic drug discovery due to 
their remarkable stability towards nucleases and proteases and have 
many desirable properties, there are some drawbacks which have to 
be answered in order to have these macromolecules ready as drug 
candidates. Current PNAs exhibit poor cellular uptake14-15 in vitro and 
poor bioavailability in vivo. This inherent limitation has prevented 
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widespread application of PNAs as therapeutics as well as in basic 
research. Unmodified PNA oligomers are essentially not taken up by 
eukaryotic or prokaryotic cells in vitro and when delivered in animals 
in vivo (intravenous or intraperitoneal) they are quickly excreted 
through the kidneys. This is partly attributed to the uncharged 
property of the peptide nucleic acids. In comparison, Nucleic acid 
oligonucleotides are negatively charged phosphates, and can readily 
penetrate through the cell membrane when complexed with positively 
charged lipids. To solve this problem some researchers synthesized 
positively charged PNAs based on lysine and arginine residues16-19. 
Inspired by the idea to increase cellular uptake by introducing the 
positively charged species into the PNA, we were interested in 
investigating the cellular uptake of cysteine based PNAs abbreviated as 
CPNAs.  
 
 
Figure 4.3. Proposed structure of cysteine based PNA (CPNA) 
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 The reason behind selecting cysteine is the presence of thiol 
group. This gives us an easy entry to synthesize more varied PNAs by 
using a variety of alkyl groups from a simple methyl group to the long 
poly-ether side chain as well as the guanidine-based side chain shown 
in Figure 4.3. 
 
4.2 Results and discussion: 
4.2.1 Synthesis of standard PNA monomers:- 
The strategy of PNA synthesis is based on solid phase chemistry. 
For this strategy to work, protected PNA monomers were synthesized 
based on the ethylene diamine precursor.20 The monomers were 
synthesized following the standard protocols in the literature. Fmoc-
based monomers are especially needed to monitor the oligomerization 
using UV-based probes.21  
Readily available ethylene diamine is mono protected with di-t-
butyl carbonate anhydride to 4.1 and further protection of 1o amine 
group with Fmoc-Cl yielded 4.2 in very good yields. Deprotection of 
the Boc group and subsequent alkylation with tert-butyl bromo acetate 
gave mono alkylated amine 4.4 as major product in very good yields. 
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Submonomer 4.4 is coupled with orthogonally protected nucleobase 
acetic acids to get compounds 4.5a-d. Deprotection of tertiary butyl 
ester in mild acid conditions gave desired monomers 4.6a-d in 
excellent yields. (Scheme 4.1)22-24  
 
 
 
Scheme 4.1 Synthesis of Fmoc protected PNA monomers  
 
Synthesis of PNA monomers for Boc based solid phase synthesis 
are started with the common intermediate 4.1. In this scheme, 
compound 4.1 is reacted with methyl bromo acetate to give 
submonomer 4.7 in very decent yields which is reacted with 
orthogonally protected nucleobase acetic acids using uranium complex 
HATU as coupling agent to get compounds 4.8a-d in very good yields. 
(Scheme 4.2).25 
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Scheme 4.2 Synthesis of Boc protected PNA monomers 
 
4.2.2 Synthesis of CPNA monomers: 
 
Cysteine-based PNA monomers are synthesized starting from the 
commercially readily available S-Trityl-N-Boc L-cysteine. (Scheme 4.3) 
Synthesis involves the activation of carboxylic acid with DCC followed 
by attack of amine nucleophile to enable the formation of amide 
4.1026. Upon selective reduction of amide 4.10 with etherated borane 
yielded amine 4.11 in very good yields.27 Alkylation of the amine via 
SN2 reaction using DIEA as base gave the desired mono alkylated ester 
4.12 in moderate yields. Selective unmasking of thiol group and 
subsequent alkylation with methyl iodide gave submonomer 4.14 in 
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decent yields.28 The coupling of orthogonally protected nucleobase 
acetic acids to the submonomer 4.14 gave corresponding methyl 
esters 4.15a-d in pretty good yields. Methyl esters were hydrolyzed in 
alkaline conditions to get CPNA monomers 4.16a-d in very good 
yields.29 
 
 
Scheme 4.3 Synthesis of novel cysteine PNA monomers 
 
4.2.3 Synthesis of novel polyether side chain: 
Oligo-ethers are known to have water solubility compared to the 
alkyl analogues because of the presence of oxygen group which can 
form hydrogen bonds with the water in biological systems.30-31 This 
property encouraged us to come up with a new alkyl group 4.21 
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(Scheme 4.4) for our ongoing PNA synthesis. Synthesis of the 
compound 4.21 starts with the commercially available 3-
bromopropanamine salt. 3-bromopropanamine hydrobromide salt was 
reacted with di-t-butyl dicarbonate in aqueous medium in the presence 
of sodium bicarbonate to afford quantitative yields of 4.17. Excess 
sodium bromide was used to make sure the bromide is not hydrolyzed 
to the corresponding hydroxide. Bromide 4.17 was alkylated onto 
triethylene glycol monomethyl ether 4.18 using sodium hydride to get 
4.19 in decent yields. Deprotection of the Boc group and subsequent 
reaction with bromo acetyl bromide gave 92% of the amide 4.21.32 
 
 
Scheme 4.4 Synthesis of novel polyether side chain 
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Novel side chain 4.21 can be alkylated onto 4.13 to achieve 
novel cysteine based monomers and further achieve PNAs with novel 
properties as to achieve the goals of this project. 
4.3 Solid phase synthesis of PNAs 
 
Standard solid phase synthesis protocol was followed for the 
synthesis of PNA oligomers for both normal as well as cysteine based 
PNA synthesis. The Symphony instrument from Protein Technologies 
Inc was used for the synthesis of Fmoc based methods on MBHA resin. 
Manual synthesis used the Boc strategy. MBHA resin was swollen in 
NMP for 45 minutes and was downloaded with Fmoc-Lys(Boc)-OH 
before growing PNA chain. Substitution level of approximately 0.15 
mmol/g was maintained so as to achieve the best results as reported 
in the literature. Fmoc deprotection was then performed using 
piperidine (20%) and DBU (2%) in NMP. Coupling of monomers with 
protecting group was carried out with excess of reagents (at least five 
fold excess). After the coupling is complete the resin was washed with 
necessary solvents and the same cycle continued until the desired 
length and sequence was achieved. After the final coupling cycle PNA 
was global deprotected and cleaved from the resin using TFA, DMS and 
TFMSA  
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 4.4. Solid phase synthesis results 
 
 
Table 4.1. Solid phase synthesis of PNAs 
 
4.5 Conclusion 
 
Syntheses of standard PNA monomers and novel Cysteine PNA 
monomers were successfully achieved. Optimizations were done to 
synthesize newly designed CPNA monomers with varying alkyl groups 
on sulphur group. Partially successful results were tabulated above and 
the schemes mentioned and developed for the synthesis of monomers 
will be utilized in the future synthesis of PNAs. 
 
 
113 
 
4.6 Experimental procedures 
 
 
 
 
(2-Amino-ethyl)-carbamic acid tert-butyl ester (4.1): To the ice 
cold solution of ethylene diamine (13.48 g, 224.3 mmol) in 250 mL of 
tetrahydrofuran was added a solution of di-t-butyl carbonate anhydride 
(10.0 g, 46 mmol) in 50 mL of tetrahydrofuran over a period of 25 
minutes. The reaction was continued at 0 oC for 3 hours and then 
brought to ambient temperatures and continued for 20 more hours. 
Upon complete consumption of the di-t-butyl carbonate anhydride, the 
reaction mixture was concentrated under reduced pressure. The 
residue obtained was dissolved in ethyl acetate (150 mL) and washed 
with water (4×45 mL). The aqueous layer was back extracted with 
ethyl acetate; organic portions were mixed, dried over anhydrous 
sodium sulphate (Na2SO4), and concentrated under reduced pressure. 
The crude product was flash chromatographed to give mono Boc 
protected amine 4.1 in good quantities, 5.8 g (79%). 1H NMR (DPX 
250 MHz, CDCl3) δ 5.35 (bs, 1H) 3.16 (m, J=5.75, 2H), 2.78 (t, J=5.5, 
2H), 1.45 (s, 9H), 1.3 (s, 2H). 13C NMR (DPX 250 MHz, CDCl3) δ 
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156.3, 78.9, 43.2, 41.7, 28.3. LCMS (ESI) m/z calcd for C7H16N2O2 is 
160.1, found 161.2 [M+H]+ 
 
 
 
tert-Butyl N-[2-(N-9-fluorenylmethoxycarbonyl) amino ethyl] 
glycinate (4.2): To the ice cold solution of (2-amino-ethyl)-carbamic 
acid tert-butyl ester 4.1 (0.5 g, 3.120 mmol) in 100 mL of dry 
dichloromethane was added diisopropylethylamine (0.443 g, 3.43 
mmol). To the resulting solution of 9-fluorenylmethyl chloroformate in 
7 mL of dichloromethane was added over a period of 15 minutes. The 
reaction was stirred at 0 oC for two hours. After the reaction was 
complete, the same was diluted to 150 mL with dichloromethane and 
washed with 45 mL of half saturated brine solution. The organic layer 
was dried over anhydrous Na2SO4 and concentrated. The crude 
product was purified by precipitation using ethyl acetate and hexanes 
to get 1.19 g (90.75%) of 4.2 as a white fluffy solid. 1H NMR (DPX 250 
MHz, CDCl3) δ 7.78-7.72 (d, 2H, J=7.5); 7.62-7.56 (d, 2H, J=7.5); 
7.44-7.24 (m, 4H); 5.22 (bs, 1H); 4.82 (bs, 1H); 4.42 (d, 2H, 
J=6.75); 4.21 (t, 1H, J=5.5); 3.28 (bs, 4H); 1.44 (s, 9H).   
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2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl-ammonium 
chloride (4.3):- A solution of orthogonally protected ethylene 
diamine 4.2 (0.5 g, 1.307 mmol) in 15 mL of 1, 4-dioxane was cooled 
to 0 oC. HCl gas was passed through the solution for 4-5 minutes and 
reaction was brought to ambient temperature by removing the ice 
bath. The reaction was monitored by TLC for the progress. After 
complete consumption of the starting material, in about 4 hrs, solvent 
was removed under reduced pressure and the product was used in the 
next step after drying under high vacuum to give pure product 4.3 as 
white solid (~ quantitative yields). 1H NMR (DPX 250 MHz CDCl3) δ 
7.84 (d, 2H, Fmoc Ar CH); 7.65 (d, 2H, Fmoc Ar CH); 7.44-7.27 m, 
5H, Fmoc Ar CH, NHFmoc); 4.42 (d, 2H, J=6.5, Fmoc CH2); 4.22 (t, 
1H, J=6.5, Fmoc, CH2); 3.37 (t, 2H, CH2-NHFmoc); 3.30 (bs, 3H, 
NH3); 3.02 (t, 2H, CH2-NH3).  
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tert-Butyl N-[2-(N-9-fluorenylmethoxycarbonyl) aminoethyl] 
glycinate ester (4.4):-To a cold solution of 4.3 (0.5 g, 1.3 mmol) in 
THF (30 mL) were added diisopropylethylamine (0.432 ml, 2.6146 
mmol), tetrabutylammonium iodide (0.155 g, 0.156 mmol) and tert-
butyl bromoacetate (0.195 ml, 1.3073 mmol) under stirring. Reaction 
was continued for 10 hrs at 0 oC and then brought to ambient 
temperature. Reaction mixture was concentrated under reduced 
pressure and flash chromatographed to get the desired mono alkylated 
product 4.4 as white semi-solid (0.181 g, 36%). 1H NMR (DPX 250 
MHz CDCl3) δ 7.67 (d, 2H, J=7.25, Fmoc Ar CH); 7.52 (d, 2H, J=7.25, 
Fmoc Ar CH); 7.35-7.16 (m, 5H, Fmoc Ar CH, NH); 5.39 (bs, 1H, NH); 
4.31 (d, 2H, J=6.75, Fmoc CH2); 4.13 (t, 1H, J=6.75, Fmoc CHO); 
3.21 (bs, 1H, NH); 2.67(t, 2H, CH2) 1.92 (s, 2H, NHCH2CO); 1.40 (s, 
9H, tBu).  
 
General procedure for nucleo-base coupling (4.5a-d):- DIEA was 
added to a solution of Cbz protected nucleo-base acetic acid, HATU 
and compound 4.4 in DMF at room temperature. The reaction was 
monitored for its progress. Starting material was completely consumed 
within 20–25 minutes. Solvent was removed under high vacuum and 
the residue was dissolved in ethyl acetate and washed with saturated 
brine solution. The organic layer was dried over anhydrous Na2SO4 and 
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concentrated. Flash column chromatography of the crude gave coupled 
products 4.5a-4.5d in 65-95% yield.  
 
 
 
 
{[2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl]-[2-(5-
methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-
amino}-acetic acid tert-butyl ester (4.5a) white solid, 96% yield. 
1H NMR (DPX 250 MHz, DMSO-d6) δ 7.89 (d, 2H, J=7.5 Fmoc Ar CH); 
7.68 (d, 2H, J=7.5, Fmoc Ar CH); 7.46-7.23 (m, 5H, Fmoc Ar CH, NH); 
4.64 (s, 1H, CH); 4.45 (s, 1H); 4.32 (d, 2H, J=, Fmoc CH2); 4.22 (t, 
1H, J=, Fmoc CH), 1.73 (s, 3H, CH3); 1.45-1.39 (ss, 9H, -C(CH3)3). 
13C NMR (DPX 250 MHz, DMSO-d6) δ 167.9, 167.2, 164.3, 156.2, 
150.9, 143.8, 142.1, 140.7, 127.6, 127.0, 125.1, 120.1, 108.1, 81.9, 
80.9, 48.7, 47.6, 46.9, 27.6. 
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 4.5b 
{[2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-
amino}-acetic acid tert-butyl ester (4.5b) white slid, 94% yield. 
1H NMR (DPX 250 MHz, CDCl3) δ 10.81 (s, 1H), 7.92 (m, 3H), 7.75 (d, 
2H), 7.62-7.21 (m, 9H), 7.02 (d, 1H), 5.23 (s, 2H), 4.81 (s, 1H), 4.66 
(s, 1H), 4.44-4.25 (m, 4H), 3.93 (s, 2H), 3.46 (2H), 3.1 (2H),  1.42 
(s, 9H).  
 
{[2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-acetyl]-[2-(9H-fluoren-9-
ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid tert-butyl 
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ester (4.5c) white solid, 82% yield. 1H NMR (DPX 250 MHz, MeOD-d4) 
δ 11.35 (1H, NH); 7.87(d, 2H); 7.81 (d, 1H); 7.43-7.34 (m, 9H); 5.24 
(3H); 5.08 (s, 1H); 4.43-4.18 (m, 4H); 3.96 (s, 1H); 1.53-1.34 (s, 
9H).  
 
{[2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-[2-(9H-
fluoren-9-ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid 
tert-butyl ester (4.5d) white solid, 87% yield. 1H NMR (DPX 250 
MHz, MeOD-d4) δ 10.67 (s, 1H, NH); 8.55 (s, 1H); 8.32 (s, 1H); 7.89 
(d, 2H, J=7.5); 7.68 (m, 2H); 7.51-7.21(m, 12H); 5.35 (s, 1H); 5.25 
(s, 1H); 4.42-4.25 (m, 4H); 4.12-3.94(m, 2H); 3.64 (s, 1H); 2.02 (s, 
2H); 1.53-1.35 (9H). 
General procedure for the deprotection of t-butyl esters 4.5a-d: 
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To a stirred solution of ester 4.5 in dichloromethane was added TFA at 
ice cold temperatures. After the completion of deprotection TFA was 
removed under reduced pressure. The residue was dissolved in DCM 
and subjected to rotary evaporation and the same was repeated 3-5 
times so as to remove the TFA to the maximum. And the crude residue 
was subjected to flash column chromatography to get pure compounds 
4.6a-d as solids. 
 
{[2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl]-[2-(5-
methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-
amino}-acetic acid (4.6a) white solid, 92% yield. 1H NMR (DPX 250 
MHz, DMSO-d6) δ 11.02 (s, 1H), 7.35 (1H), 7.02 (1H), 4.76 (s, 2H), 
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4.57 (1H), 4.33 (s, 1H), 4.02 (2H), 3.74 (s, 1H), 3.63 (s, 3H), 3.44-
3.03 (m, 3H), 1.75 (s, 3H), 1.4 (s, 9H). 
 
 
{[2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-
amino}-acetic acid (4.6b) white solid, 87% yield. 1H NMR (DPX 250 
MHz, DMSO-d6) δ 10.93 (bs, NH, 1H), 7.94 (1H), 7.55-7.44 (5H), 7.0 
(1H), 5.23 (s, 2H), 4.82 (s, 2H), 4.12 (s, 2H), 3.65 (s, 3H), 3.45-2.93 
(m, 4H), 1.42 (s, 9H). 
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{[2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-acetyl]-[2-(9H-fluoren-9-
ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid (4.6c) 
yellowish solid, 86% yield. LCMS (ESI) m/z calcd for C24H29N7O7 is 
527.2, found 528.1 [M+H]+. 
 
{[2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-[2-(9H-
fluoren-9-ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid 
(4.6d) white solid, 84% yield. 1H NMR (Inova 400 MHz, DMSO-d6) δ 
8.56 (d, J = 19.3 Hz, 1H), 8.49–8.45 (m, 1H), 7.84 (d, J = 7.5 Hz, 
2H), 7.67–7.61 (m, 2H), 7.50–7.46 (m, 1H), 7.45–7.42 (m, 2H), 
7.39–7.34 (m, 4H), 7.34–7.30 (m, 1H), 7.29–7.25 (m, 2H), 5.35 (s, 
1H),5.19 (d, J = 18.2 Hz, 3H), 4.33 (d, J = 7.1 Hz, 2H), 4.28–4.14 
(m, 3H), 3.97 (s, 1H),3.55–3.50 (m, 1H), 3.33 (d, J = 15.4 Hz, 2H). 
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Methyl N-(2-Boc-aminoethyl) glycinate (4.7):- 
Diisopropylethylamine (DIEA) (2.47 ml, 15.0 mmol) was added to an 
ice cold solution of (2-amino-ethyl)-carbamic acid tert-butyl ester 4.1 
(2.0 g, 12.5 mmol) in 100 ml of dry tetrahydrofuran at 0 oC under 
nitrogen atmosphere. To the above solution, methyl bromoacetate 
(1.18 ml, 12.5 mmol) was added over a period of 15 minutes followed 
by the addition of tetra butyl ammonium iodide, TBAI (0.23 g, 0.6245 
mmol). The temperature is maintained near 0 oC for 9 hrs and then 
brought to ambient temperature and continued for another 10 hours. 
Solvent is stripped off under reduced pressure and the crude is flash 
column chromatographed to get (2.1 g, 72%) of the mono alkylated 
compound 4.7 along with unwanted di alkylated compound. 1H NMR 
(DPX 250 MHz, CDCl3) δ 5.13 (bs, 1H, NH); 3.75 (s, 3H, CH3); 3.44 (s, 
2H, CH2); 3.23 (q, 2H, CH2, J=5.75); 2.73 (t, 2H, CH2, J=5.5); 2.18 
(bs, 1H, NH); 1.44 (s, 9H); 
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Same procedure was followed for coupling of 4.7 with nucleobase 
acetic acids to make 4.8a-d as mentioned in the synthesis of 4.5a-d. 
 
{(2-tert-Butoxycarbonylamino-ethyl)-[2-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid 
methyl ester (4.8a) white solid, 93% yield. 1H NMR (DPX 250 MHz, 
DMSO-d6), δ 11.0 (s, 1H), 7.3 (1H), 7.0 (1H), 4.7 (1H), 4.1 (1H), 3.7 
(1H), 3.6 (s, 3H), 3.5-3.0 (m, 5H), 1.8 (s, 3H), 1.4 (s, 9H) 
 
[[2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic acid 
methyl ester (4.8b) white solid, 91% yield. 1H NMR (DPX 250 MHz, 
MeOD-d4) δ 10.8 (s, 1H), 7.8 (d, 1H), 7.4 (m, 5H), 7.0 (d, 1H), 5.2 (s, 
2H), 4.6 (s, 1H), 4.5-3.5 (m, 6H), 3.4 (s, 3H), 2.5 (s, 2H), 1.4 (s, 9H).  
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 [[2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-acetyl]-(2-tert-
butoxycarbonylamino-ethyl)-amino]-acetic acid methyl ester 
(4.8c) white solid, 77% yield. 1H NMR (DPX 250 MHz, DMSO-d6), δ 
11.5 (s, 1H), 11.4 (s, 1H), 7.8 (s, 1H) 7.6-7.3 (m, 5H), 5.3 (s, 2H), 
4.1-3.2 (m, 11H), 1.4 (s, 9H) 
 
[[2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-(2-tert-
butoxycarbonylamino-ethyl)-amino]-acetic acid methyl ester 
(4.8d) white solid, 86% yield. 1H NMR (DPX 250 MHz, DMSO-d6) δ 
10.7 (s, 1H), 8.5 (s, 1H), 8.2 (s, 1H), 8.0 (s, 1H), 7.8-7.2 (m, 5H), 5.2 
(s, 2H), 4.5-4.0 (m, 4H), 3.3 (s, 3H), 2.5 (s, 2H), 1.4 (s, 9H). 
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General procedure for the deprotection of methyl esters 4.8a-d: 
To a stirred solution of ester 4.8a-d in THF/H2O was added 1M NaOH in 
water at ice cold temperatures. After the completion of deprotection 
THF was removed under reduced pressure. The water layer was 
extracted with EtOAc to remove any impurities and the water layer 
was acidified to ρH 4.0 and the product was extracted into EtOAc and 
the organic solvent was dried over anhydrous Na2SO4 and removed 
under reduced pressure. The crude product was chromatographed if 
necessary to obtain pure products 4.9a-d as solids. 
 
 
{(2-tert-Butoxycarbonylamino-ethyl)-[2-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid 
(4.9a) white solid, 94% yield. 1H-NMR (DPX 250 MHz, DMSO-d6)12.1 
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(s, 1H), 10.2 (bs, 2H), 7.1 (1H), 4.4 (m, 4H), 3.5-3.2 (m, 4H), 1.9 
(2H), 1.4 (9H). LCMS (ESI) m/z 285.1 [M+H]+. 
 
[[2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic acid 
(4.9b) white solid, 93% yield. 1H NMR (DPX 250 MHz, DMSO-d6), δ 
11.0 (bs, 2H), 7.9 (m, 1H), 7.5-7.3 (m, 5H), 7.1-6.9 (m, 1H), 5.2 (s, 
2H), 4.8 (s, 2H), 4.0 (s, 2H), 3.3-3.1(m, 4H), 1.4 (s, 9H), LCMS (ESI) 
m/z 504.2 [M+H]+. 
 
 
[[2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-acetyl]-(2-tert-
butoxycarbonylamino-ethyl)-amino]-acetic acid (4.9c) white 
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solid, 94% yield. 1H-NMR (DPX 250 MHz, DMSO-d6), δ 11.0 (1H), 7.8 
(s, 1H), 7.5-7.3 (m, 5H), 5.2 (s, 2H), 4.0 (s, 2H), 3.9-3.7 (m, 2H), 
3.6-3.2 (m, 4H), 1.4 (s, 9H); LCMS (ESI) m/z 544.2 [M+H]+. 
 
 
[[2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-(2-tert-
butoxycarbonylamino-ethyl)-amino]-acetic acid (4.9d) white 
solid, 82% yield. LCMS (ESI) m/z calcd for C24H29N7O7 is 527.21, found 
528.1 [M+H]+. 
 
 
 
(R)-tert-butyl 1-amino-1-oxo-(tritylthio) propan-2-ylcarbamate 
(4.10):- To a solution of commercially available S-trityl Boc Cysteine 
(2.0 g. 4.31 mmol), HOBt (0.70 g, 5.17 mmol) and DCC (1.07 g, 5.18 
mmol) in THF (10ml) was added 28 % NH4OH (0.44 ml, 6.46 mmol) at 
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0 oC. After 2 hr of stirring at 0 oC, the reaction mixture was filtered 
through Celite and filtrate was concentrated, diluted with ethyl 
acetate, and washed with water and brine. Organic layer was then 
dried over anhydrous sodium sulphate and concentrated under 
reduced pressure. The crude is flash chromatographed to get pure 
compound 4.10 as a white solid in nearly quantitative yields. (1.95 g, 
98%) 1H NMR (DPX 250 MHz, CDCl3) δ 7.54-7.24 (15H, C6H5); 6.03 
(bs, 1H); 5.55 (bs, 1H); 4.87 (bs, 1H); 3.93 (bs, 1H); 2.02 (s, 2H, 
CH2) 1.44 (s, 9H); 13C NMR (DPX 250 MHz, CDCl3) δ 173.83, 155.42, 
144.42, 130.04, 129.60, 128.10, 126.93, 80.34, 67.24, 53.22, 33.80, 
28.33.; LCMS (ESI) m/z calcd for C27H30N2O3S is 462.19, found 485.16 
[M+Na]+. 
 
 
 
(R)-tert-butyl-1-amino-3(tritylthio) propan-2-ylcarbamate 
(4.11): - To the solution of 4.10 (1 g, 2.16 mmol) in anhydrous THF 
(5 ml) was added 1M Borane-THF complex (5.4 ml, 5.4 mmol) at 0 oC 
and stirred at 0 oC for 3 hrs. The reaction was heated to 60 oC and 
refluxed for 12 hrs. The reaction mixture was cooled to 0 oC and 
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quenched by slow addition of methanol. The oil obtained upon 
repeated dilutions and concentrations (2-3 times) with methanol, was 
subjected to water work up (pH 8.5) followed by flash column 
chromatography to afford the corresponding amine 4.11 (0.58 mg, 60 
%). 1H NMR (DPX 250 MHz, CDCl3) δ 7.40 (D, J=7.27 Hz, 6H), 7.19 
(ddd, J=14.29, 5.76 Hz, 9H), 5.27-4.85 (bs, 1H), 3.55 (bs, 2H), 2.35 
(tt, J=17.88, 8.99 Hz, 2H), 2.63 (d, J=5.68 Hz, 2H), 1.39 (s, 3H). 13C 
NMR (DPX 250 MHz, CDCl3) δ 155.57, 144.65, 79.35, 66.79, 64.35, 
60.39, 44.40, 34.37.LCMS (ESI) m/z calcd for C27H32N2O2S is 448.21, 
found 449.22 [M+H]+. 
 
 
 
(2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propylamino)-
acetic acid methyl Ester (4.12):-To the solution of 4.11 (1.66 g, 
3.7 mmol) in THF (40 ml) at 0 oC was added methyl bromoacetate (35 
ml, 3.7 mmol, dissolved in 5 ml) followed by the addition of DIEA 
(0.672 ml, 4.070 mmol) and stirring was continued for 7 hrs. Reaction 
was brought to ambient temperature and continued for another 10 
hrs, after which it was concentrated to dryness. The residue obtained 
was dissolved in ethyl acetate and washed with saturated brine 
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solution. Aqueous layer was back extracted into ethyl acetate. Organic 
layer was dried over anhydrous sodium sulfate and concentrated to 
give crude product which was purified by flash column 
chromatographed to get pure compound 4.12 (0.721 g, 37.43 %). 1H 
NMR (DPX 250 MHz, CDCl3) δ 7.54-7.12 (m, Ar 15H); 4.74 (bs, NH, 
1H); 3.73 (s, CH3, 3H);3.33 (d, NHCH2CO, 2H); 2.72-2.26 (m, 3H) 
1.64 (s, SCH2, 2H); 1.44 (s, tBu, 9H). 13C NMR (DPX 250 MHz, CDCl3) 
δ 172.8, 155.6, 79.48, 51.8, 51.2, 50.8, 49.7, 36.9, 28.4, 16.3, HRMS 
(ESI) m/z calcd for C30H36N2O4S is 520.24, found 521.2 [M+H]+. 
 
 
 
(2-tert-Butoxycarbonylamino-3-methylsulfanyl-propylamino)-
acetic acid methyl ester (4.14):-To the solution of compound 4.12 
(0.700, 1.34 mmol) in 100 ml of dry dichloromethane was added TFA 
(1.6 ml) at 0 oC over a period of 7 minutes which turned into yellow 
color. To the above solution, triethylsilane (0.436 ml) was added over 
a period of 3 minutes. The reaction mixture turned to a pale yellow 
from dark yellow color. Reaction was complete in 12 minutes by TLC. 
Reaction mixture was concentrated to half of its volume and diluted 
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with 50 ml of DCM. Again concentrated and repeated the same thing 
for four times to make sure TFA was removed as much as possible. 
The crude compound 4.13 was dried under high vacuum and taken to 
the next step without further purification. The above residue was 
dissolved in 10 ml of Methanol and cooled to 0 oC to which 3.36 ml of 
1N NaOH was added followed by the addition of 0.16 ml of 
iodomethane. The reaction was over in 15 minutes. The reaction 
mixture was neutralized by adding 20% citric acid solution and the 
solvent was removed under vacuum. The residue was dissolved in 
ethyl acetate and washed with saturated brine solution. The organic 
layer was dried over anhydrous sodium sulphate and concentrated. 
Flash chromatography gave pure compound 4.14 (0.22 g, 56%). 1H 
NMR (DPX 250 MHz, CDCl3) δ 3.73 (s, CH3, 3H); 3.53 (d, 2H); 2.91-
2.62 (m, 3H); 2.38 (bs, 2H); 2.25 (s, 3H); 1.93 (s, tBu, 9H); LCMS 
(ESI) m/z calcd for C12H24N2O4S is 292.14, found 293.1 [M+H]+. 
 
 
Representative base coupling procedure: Diisopropylethylamine 
(0.37 ml, 0.29 mmol) was added to a stirring solution of 4.14 (0.22 g, 
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0.75 mmol), thymine acetic acid (0.207 g, 1.1278 mmol) and HATU 
(0.343g, 0.90 mmol) in DMF (3 ml) at ambient temperatures. The 
reaction mixture turned yellow. TLC showed the reaction was complete 
in 10 minutes. DMF was removed under high vacuum without heating. 
The crude was dissolved in ethyl acetate (150 ml) and washed with 
saturated brine (7 ml) The layers were separated and the organic layer 
was dried over anhydrous sodium sulphate and concentrated. Flash 
chromatography of the crude gave pure compound 4.15a as white 
solid (0.29 g, 87.8%). The same procedure is used to synthesize 
4.15a-d compounds. 
 
4.15a: product as white solid, 0.29 g, 87.8%. 1H NMR (DPX 250 MHz, 
CDCl3) δ 7.33 (1H), 4.42 (s, 1H), 3.85 (s, 2H), 4.34-3.96 (m, 2H), 
3.74 (s, 3H), 3.33 (1H), 2.74-2.55 (m, 2H), 2.27 (s, 2H), 2.13 (2H), 
1.93 (s, 3H), 1.53 (s, tBu, 9H); LCMS (ESI) m/z calcd for C19H30N4O7S 
is 458.18, found 458.19 [M+H]+, 481.17 [M+Na]+. 
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 4.15b: pure product as white solid, (0.168 g, 85.27%).1H NMR (DPX 
250 MHz, CDCl3) δ 8.71(d, NH), 8.35 (NH), 7.85 (d, CH), 7.56-7.23 
(Ar, 5H),4.7( 1H),  4.41 (d, CH), 4.16 (CH2), 3.80 (CH2), 3.75 (CH2), 
3.70 (CH2), 2.21 (CH2), 2.02 (CH3), 1.45 (tBu); LCMS (ESI) m/z calcd 
for C26H35N5O8S is 577.22, found 578.2 [M+H]+. 
 
 
4.15c: (0.33 g, 56.21%); 1H NMR (DPX 250 MHz, MeOD-d4) δ 8.8 (s, 
1H), 8.4 (1H), 7.6-7.2 (m, 5H), 5.5 (1H), 5.3 (1H), 4.0-3.6 (4H), 3.4-
3.1 (m, 2H), 3.0 (2H), 2.9 (3H), 1.4 (s, 9H); LCMS (ESI) m/z calcd for 
C27H35N7O8S is 617.22, found.618.2 [M+H]+. 
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Hydrolysis of methyl esters was performed following the same 
procedure employed for the hydrolysis of 4.8a-d to get pure 
compounds 4.16a-d. 
 
(4.16d): colorless solid, 84% yield. 1H-NMR (DPX 250 MHz, MeOD-d4) 
δ 8.8 (1H), 8.6 (1H), 8.0 (2H), 7.6-7.3 (3H), 5.5 (2H), 5.3 (2H), 4.3-
3.6 (5H), 3.0 (2H), 2.8 (2H), 2.2 (3H), 1.4 (9H)  
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N-tert-butoxycarbonyl-3-bromopropylamine (4.17): - A solution 
of sodium bicarbonate (0.39 g, 4.64 mmol) in 15 ml of water was 
added to 3-bromopropylamine hydrobromide (1.0 g, 4.56 mmol) in 20 
ml of chloroform. To the above mixture, di tert-butyl dicarbonate 
anhydride (1.0 g, 4.58 mmol) was added at ambient temperature, with 
vigorous stirring, followed by the addition of sodium bromide (1.0 g, 
9.72 mmol). The reaction mixture was refluxed for 18 hrs and then 
brought to ambient temperature and the layers were separated. The 
aqueous layer was extracted with chloroform (2x20 ml). The organic 
layers were mixed and dried over anhydrous sodium sulphate and 
concentrated to give pure compound 4.17 without any further 
purification (1.04 g, ~100%) 1H NMR (DPX 250 MHz, CDCl3) δ 4.71 
(bs, 1H, NH); 3.44 (t, 2H, J=6.5); 3.27 (q, 2H, J=6.5); 2.05 (m, 2H, 
J= 6.5); 1.44 (s, 9H, CH3);  
 
 
 
3-(2-(2-(2-Methoxy-ethoxy)-ethoxy)-ethoxy)-propyl)-carbamic 
acid tert-butyl ester (4.19): - Sodium hydride (60% in mineral oil, 
58 mg, 1.461 mmol) was added to an ice cold solution of triethylene 
137 
 
glycol monomethyl ether 4.18 (0.2 g, 1.218 mmol) in tetrahydrofuran 
(15 ml) and stirred for five minutes. N-tert-Butoxycarbonyl-3-
bromopropylamine 4.17 (0.29 g, 1.218 mmol) was added to the above 
mixture at the same temperature. The reaction was gradually brought 
to ambient temperature and stirred for another 8 hrs. The reaction 
mixture was then cooled to 0 oC and quenched by slow addition of 
methanol (10 ml) and concentrated to dryness. The residue was 
dissolved in ethyl acetate and washed with saturated brine solution. 
The organic layer was dried over anhydrous sodium sulphate and 
concentrated. Flash column chromatography yielded the pure 
compound 4.19 (0.20 g, 52%). 1H NMR (DPX 250 MHz, CDCl3) δ 5.14 
(bs, 1H, NH); 3.73-3.54 (m, 16H) 3.42 (s, 3H, CH3); 3.26 (q, 2H, 
J=6); 1.76 (p, 2H, J=6.25, 6.0); 1.44 (s, 9H)  
 
 
 
3-{2-[2-(2-Methoxy ethoxy) ethoxy-]-ethoxy}-propylamine 
hydrochloride (4.20): - Dry HCl gas was passed into an ice cold 
solution of compound 4.19 (0.179 g, 0.55 mmol) dissolved in 1,4-
dioxane (25 ml) for five minutes. Progress of the reaction was 
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monitored by TLC. The reaction was complete in 25 minutes. The 
solvent was removed under reduced pressure and dried under high 
vacuum. The compound 4.20 was used in the next step without any 
further purification.  
 
 
 
3-{2-[2-(2-Methoxy ethoxy) ethoxy-]-ethoxy}-propylamine 
bromo acetamide (4.21):- The above hydrochloride salt (4.20) is 
dissolved in benzene (20 ml) and cooled to 0 oC. To the solution, was 
added potassium carbonate (0.153 g, 1.114 mmol) followed by the 
addition of bromo acetyl bromide (0.11 g, 0.55 mmol). The reaction 
was brought to ambient temperature and stirred for 8 hrs. TLC showed 
there was no starting material left. Solids were filtered and the 
solution was concentrated under reduced pressure. The residue was 
dissolved in ethyl acetate and washed with water and saturated brine 
solution. Layers were separated and the organic layer was dried over 
anhydrous sodium sulphate and concentrated under reduced pressure 
to give crude which was purified by flash column chromatography to 
give the amide compound 4.21. 1H NMR (DPX 250 MHz, CDCl3) δ 9.33 
(bs, 1H, NH); 4.34-3.52 (16H); 3.43 (s, 3H, CH3); 2.13 (s, 2H, CH2); 
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13C NMR (250 MHz, CDCl3) δ 171.23, 71.76, 70.41, 70.35, 70.32, 
70.25, 69.00, 63.55, 58.84, 38.93, 28.85, 20.85. 
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APPENDIX-A: Selected 1H, 13C NMR Spectra & Mass spectra 
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2-N-(methanesulfonyl)-aminopyrimidine (2.1) 
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5-iodo-2-N-(methanesulfonyl) amino pyrimidine (2.2) 
 
 
 
 
149 
 
5-iodo-2-N-[(methanesulfonyl), (4-methoxybenzyl)] amino 
pyrimidine (2.3) 
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5-[(2-hydroxy), (2-methyl)] butynyl-2-N-[(methanesulfonyl), 
(4-methoxynenzyl)] amino pyrimidine (2.4) 
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N-(5-Ethynyl-pyrimidin-2-yl)-N-(4-methoxy-benzyl)-
methanesulfonamide (2.5) 
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N-(5-{2-[Methanesulfonyl-(4-methoxy-benzyl)-amino]-
pyrimidin-5-ylethynyl}-pyrimidin-2-yl)-N-(4-methoxy-benzyl)-
methanesulfonamide (2.6) 
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N-{5-[2-(2-Methanesulfonylamino-pyrimidin-5-yl)-ethyl]-
pyrimidin-2-yl}-methanesulfonamide (2.8) 
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5-iodo-2-amino-pyrimidine (2.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
Di-tert-butyl (5-iodopyrimidin-2-yl) dicarbamate (2.10) 
 
 
156 
 
(5-{2-[Methanesulfonyl-(4-methoxy-benzyl)-amino]-
pyrimidin-5-ylethynyl}-pyrimidin-2-yl)-di-carbamic acid di-
tert-butyl ester (2.11) 
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1H-NMR, 13C-NMR & 13C-DEPT135 (2.12) 
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159 
 
N-{5-[2-(2-Amino-pyrimidin-5-yl)-ethyl]-pyrimidin-2-yl}-N-(4-
methoxy-benzyl)-methanesulfonamide (2.13) 
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C-Chloro-N-[5-(2-{2-[methanesulfonyl-(4-methoxy-benzyl)-
amino]-pyrimidin-5-yl}-ethyl)-pyrimidin-2-yl]-
methanesulfonamide (2.14) 
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C-Chloro-N-{5-[2-(2-methanesulfonylamino-pyrimidin-5-yl)-
ethyl]-pyrimidin-2-yl}-methanesulfonamide (2.15) 
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2-N-(chloro methanesulfonyl)-aminopyrimidine (2.16) 
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 L-Serine methyl ester hydrochloride (2.19) 
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Die )
 
 
 
thyl-(phenylcarbonyl)-phosphonate (3.2
165 
 
Phosphonic acid, (2-phenyloxiranyl)-, diethyl ester (3.3) 
 
 
166 
 
(2-Phenyl-oxiranyl)-lithium phosphonate mono-ethyl ester 
(3.4)
 
 
167 
 
Diazo-phenyl-acetic acid methyl ester (3.7)
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2,3-diphenyl-oxirane-2-carboxylic acid methyl ester (3.8a)
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3-(2- thyl 
ester (3.8g) 
 
nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid me
3-(2-nitro-phenyl)-2-phenyl-oxirane-2-carboxylic acid (3.9g)
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[(Methoxycarbonyl-phenyl-methylene)-hydrazono]-phenyl-
id methyl esteacetic ac r (3.8i)
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 2,3-diphenyloxirane (3.10)
 
172 
 
β-azido-α-phenyl benzeneethanol (3.11)
173 
 
2,3-Diphenylaziridine (3.12)
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
1-Aziridinecarboxylic acid,2,3-diphenyl-, 1,1-dimethylethyl 
ester (3.13)
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N-(phenylmethyle thanamine (3.16)ne)-me
 
176 
 
Be )nzenemethanamine-4-methoxy-N-(phenylmethylene) (3.17
 
177 
 
Benzyl-benzylidene-amine (3.18)
 
178 
 
1,2-diphenyl-cyclopropanecarboxylic acid methyl ester (3.21)
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1,2-diphenyl-cyclopropanecarboxylic acid (3.22)
 
 
180 
 
(2-Amino-ethyl)-carbamic acid tert-butyl ester (4.1) 
 
 
181 
 
tert-Butyl N-[2-(N yl) amino ethyl] 
glycinate (4.2)
-9-fluorenylmethoxycarbon
 
182 
 
2-( m 
chloride (4.3)
 
 
 
 
 
 
 
 
 
 
 
9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl-ammoniu
183 
 
 tert-Butyl N-[2-(N-9-fluorenylmethoxycarbonyl) aminoethyl] 
glycinate ester (4.4)
 
 
 
 
 
 
 
 
 
 
 
184 
 
(4.5a) 
 
[2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-
amino}-acetic acid tert-butyl ester (4.5b)
 
185 
 
[2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
idin-3-yl)-
hyl]-a
[1,2,3]triazolo[4,5-d]pyrim acetyl]-[2-(9H-fluoren-9-
ylmethoxycarbonylamino)-et mino}-acetic acid tert-butyl 
ester (4.5c) 
 
 
 
 
 
 
 
 
 
 
186 
 
 [2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-[2-(9H-
fluoren-9-ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid 
tert-butyl ester (4.5d)
 
 
 
 
 
 
 
 
 
 
187 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethyl]-[2-(5-
-dihydro-2H-pyrmethyl-2,4-dioxo-3,4 imidin-1-yl)-acetyl]-
amino}-acetic acid (4.6a)
 
 
 
 
 
 
 
 
 
 
 
188 
 
 [2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-
amino}-acetic acid (4.6b)
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 [2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-[2-(9H-
fluoren-9-ylmethoxycarbonylamino)-ethyl]-amino}-acetic acid 
(4.6d)
Methyl N-(2-Boc-aminoethyl) glycinate (4.7) 
190 
 
  
 
 
 
 
 
 
 
 
 
 
 
191 
 
(2-tert-Butoxycarbony -(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin- cetyl]-amino}-acetic acid 
methyl ester (4.8a) 
lamino-ethyl)-[2
1-yl)-a
 
 
 
 
 
 
 
 
 
 
 
192 
 
 mino-2-[2-(4-Benzyloxycarbonyla oxo-2H-pyrimidin-1-yl)-
acetyl]-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic acid 
methyl ester (4.8b) 
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 2-(5-Benzyloxycarbonylamino-7-oxo-6,7-dihydro-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-acetyl]-(2-tert-
(4.8c) 
butoxycarbonylamino-ethyl)-amino]-acetic acid methyl ester 
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 2-(6-Benzyloxycarbonylamino-purin-9-yl)-acetyl]-(2-tert-
butoxycarbonyla r mino-ethyl)-amino]-acetic acid methyl este
(4.8d) 
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2-(4-Benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-
acetyl]-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic acid 
(4.9b) 
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[ -
ac d 
 
[2-(2-Benzyloxycarbonylamino-6-oxo-1,6-dihydro-purin-9-yl)
etyl]-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic aci
(4.9c)
197 
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4.15b
 
4.15c
 
 
200 
 
N-tert-butoxycarbonyl-3- romopropylamine (4.17) b
 
 
3-(2-(2-(2-Methoxy-ethoxy)-ethoxy)-ethoxy)-propyl)-carbamic 
acid tert-butyl ester (4.19)
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3-{2-[2-(2-Methoxy ethoxy) ethoxy-]-ethoxy}-propylamine 
bromo acetamide (4.21) 
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